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1 Summary 
Gamma-glutamyl peptides are widely found in plants. γ-Glutamyl-propenyl-cysteine sulfoxide 
(GPCS), a glutamyl peptide present in onion (Allium cepa L.), was identified by a bioassay-
guided fractionation in vitro to be the compound responsible for the inhibition of bone 
resorption by onion in rats. Therefore, GPCS was selected for an extended investigation in 
our studies. The aim of the first part of this work was to examine the presence of GPCS in 
various plants, which were previously shown to inhibit bone resorption in rats. A fast and 
reliable method to determine GPCS in plant material was developed and validated. GPCS 
was found in onion at various concentrations, but no GPCS was detected in the material from 
other plants.  
In the second part of the present work, the aim was to provide GPCS for further in vitro and 
in vivo studies. Small quantities (milligram-amounts) were obtained by isolation of GPCS 
from onion. As large-scale isolation (gram amounts) is not feasible under non-industrial 
conditions, and GPCS is not commercially available, an approach for synthesis was 
performed. The intermediate products S-(1-propenyl)-L-cysteine sulfoxide and Boc-L-
glutamyl-α-t-butyl-N-oxo-succinimide ester were synthesised, but unfortunately, coupling of 
these two compounds failed and the final product could not be obtained.  
The aim of the third part of this work was to examine pharmacodynamic and pharmacokinetic 
parameters of GPCS. In vitro experiments on the effects of GPCS on the activity, activation 
and recruitment of osteoclasts (OCs) were performed. The effect of GPCS on the activity of 
OCs was tested in the pit assay. GPCS, at 8 mM, significantly reduced the number of pits per 
OCs. The effect of GPCS on the activation of OCs was examined by determination of the 
OCs with actin ring(s). After incubation of the cells with 2 and 8 mM of GPCS, the percentage 
of OCs with actin rings did not change. The formation of OCs was inhibited at GPCS 
concentrations of 1 mM and higher in our experiments with CSF-1/RANKL primed bone 
marrow cells. A structure-function relationship was assessed by testing GPCS structurally 
related compounds in the same assay, namely γ-glutamyl-cysteine-ethylester, glycyl-
cysteine, allyl-cysteine, cysteine, glutamyl-glycine and glycyl-valine. All test substances 
which contained a cysteine moiety inhibited osteoclastogenesis while the others did not show 
an effect. The pharmacokinetic properties of GPCS were studied in vitro and in vivo. Within 
24 hours no change in the concentration of GPCS was observed when GPCS was incubated 
with simulated gastric acid. 24-hour incubation of GPCS with simulated intestinal fluid caused 
a 90 % decrease of the GPCS concentration, while GPCS concentration in onion incubated 
with simulated intestinal fluid decreased only by 30 %. In a pilot study with rats on the 
kinetics of GPCS in vivo, the bioavailability of orally administered GPCS was determined to 
be about 1 %. Finally, onion without GPCS and onion containing GPCS, as well as GPCS-
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structure related compounds were tested in a rat model in vivo to analyse their effect on 
bone resorption. Allyl-cysteine and γ-glutamyl-cysteine-ethylester did not inhibit bone 
resorption while 3 g of onion without GPCS and 3 g of onion containing GPCS significantly 
inhibited bone resorption.  
The in vitro results indicate that the effects of GPCS might be mediated by the cysteine 
moiety of the molecule. An in vivo oral application of pure GPCS in an aqueous solution is 
not suitable due to the low bioavailability of GPCS, however, application of GPCS embedded 
in onion might prevent cleavage of the compound and therefore increase the bioavailability. 
Because both onion without GPCS and onion containing GPCS inhibited bone resorption in 
vivo, we can postulate that the inhibition of bone resorption by onion is not exclusively 
mediated by GPCS. Future experiments using natural GPCS-free onions spiked with 
synthetic GPCS should clarify, to which extent GPCS contributes to the inhibition of bone 
resorption. 
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Osteoporosis is widely recognised as a major public health problem. It is a systemic disease 
of the skeletal system characterised by reduced bone mass and microarchitectural 
deterioration of bone tissue which leads to an increased risk of fractures. Bone loss occurs 
because the equilibruim of bone formation and bone resorption is shifted to one side – to a 
decrease of bone formation and/or an increase of bone resorption. Dietary components and 
herbal products were reported to have positive influence on this process, particularly by 
inhibiting bone resorption [Putnam 2007], and thus may prevent osteoporosis and its 
consequences.  
Several herbs and vegetables, among them onion (Allium cepa L.), were shown to inhibit 
bone resorption in rats [Muhlbauer 1999, Muhlbauer 2003a, Muhlbauer 2003b]. This effect 
was independent of their base-excess [Muhlbauer 2002] and an effect of flavonoids, 
especially rutin was unlikely to be the cause, as shown in previous experiments [Muhlbauer 
2001]. To isolate and identify the substance in onion which might be responsible for the 
inhibition of bone resorption, a bioassay-guided fractionation was performed. γ-Glutamyl-
propenyl-cysteine sulfoxide (GPCS1) was identified as the active compound in vitro which 
inhibits the resorption activity of osteoclasts (OCs) [Wetli 2005].  
The aim of the first part of this PhD thesis was to examine the presence of GPCS in various 
plants, which were previously shown to inhibit bone resorption in rats. The requirement for 
this study was to develop a fast and reliable method to determine GPCS in plant material. 
In the second part, the aim was to provide GPCS for further in vitro and in vivo studies. As 
large-scale isolation (gram amounts) is not feasible under non-industrial conditions, and 
GPCS is not commercially available, an approach for synthesis was performed. 
The aim of the third part of this work was to examine whether GPCS does not only affect OC 
activity, but also its activation and recruitment. A structure-function relationship was 
assessed by testing structurally related compounds in vitro. The kinetic of GPCS was studied 
in vitro and in vivo. Finally, onion without GPCS and onion containing GPCS, as well as 
GPCS-structure related compounds were tested in a rat model in vivo to analyse their effect 
on bone resorption. 
                                               
1
 The abbreviations used in this work are given in  section 11.1 Appendix 1: List of Abbreviations. 
Introduction 3 
 
 
 
 
 
5 Introduction 
Introduction 4 
 
5.1 Allium cepa L. 
5.1.1 Botanical systematics and history 
Onion (Allium cepa L.) is a member of the Alliaceae family and belongs to the genus Allium 
which consists of about 450 species. Besides onion and garlic, also the other members of 
Allium like leek (Allium porrum L.), shallot (Allium ascalonicum L.), wild garlic (Allium ursinum 
L.) and many others are known for their unique and typical taste. Allium plants are widely 
distributed over Europe, Asia and America, and they have been used for millennia as spices, 
vegetables and for the treatment of diseases [Lanzotti 2006].  
Onions probably originate from central Asia where they were produced since 3000 B.C.. 
They were brought to Europe about 2000 years ago. Onions and garlic were first cited in the 
Codex Ebers 1550 B.C., an Egyptian medical papyrus, and there recommended to cure 
heart problems, headache, bites, worms and tumours. In ancient times onions were 
consumed in large quantities because they were thought to be sacred food. The raw plant 
was given to asthmatics and to people suffering from pulmonary diseases. The Greeks and 
Romans cherished onions as curative agents [Block 1985, Corea 2005].  
5.1.2 Bioactivity 
Today onions are important phytonutrients, and a variety of studies suggests a positive effect 
of onions in the prevention and treatment of cancer, cardiovascular diseases, asthma, 
infections and hyperlipidemia [Griffiths 2002]. It was shown that food supplementation with 
onions significantly inhibits bone resorption in rats [Muhlbauer 1999, Muhlbauer 2002]. 
Onions, their extracts or isolated compounds, are able to modulate mammalian enzyme 
systems [Teyssier 2001], may cause apoptosis and show antiinflammatory, antioxidant [Yang 
2004], antimicrobial, spasmolytic [Corea 2005], antifungal, antithrombotic, antilipidaemic [Ali 
2000], antihyperglycemic [El-Demerdash 2005] and antiparasitic properties [Lanzotti 2006, 
Rose 2005]. In traditional medicine, fresh onion juice is used against common cold, cough, 
as well as local treatment of insect bites. 
5.1.3 Chemistry 
Bulbs of Allium cepa L. consist of water (~ 90 %), carbohydrates (~ 10 %), proteins (~ 1 %) 
and fat (~ 0.1 %). They are a rich source of bioactive compounds which are the thiosulfinates 
and structurally related substances, flavonoids, sapogenins and saponins. Their biosynthetic 
pathways and metabolisms within the plant were mainly studied by chemical analysis and 
radiotracer experiments [Jones 2004].  
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Organosulphur compounds 
The typical odour of onion is developed as soon as its tissue is damaged because this 
damage leads to the release of volatile substances by enzymatic hydrolysis of non-volatile 
sulphur-containing storage compounds. These flavour precursors in onion are the odourless 
S-alk(en)yl-cysteine sulphoxides, which are typical for the Allium genus.  
Sulphur is incorporated into the plant through the roots, reduced to sulphide, and primarily 
accumulated intracellularly through cysteine into the glutathione cycle leading to the 
non-volatile gamma-glutamyl peptides. Until now 24 sulphur-containing gamma-glutamyl 
peptides have been identified in Allium ssp. [Rose 2005]. They serve not only as sulphur and 
nitrogen storage compounds [Kasai 1980] but also as intermediates in the 
S-alk(en)yl-cysteine sulphoxide synthesis [Lancaster 1989, Lancaster 1991]. The major 
gamma-glutamyl peptides in onion are GPCS and S-2-carboxypropylglutathione [Shaw 1989] 
(Figure 1). According to Lancaster et al. [Lancaster 1991] they are not present in pre-bulbing 
onion, largely increased through bulbing and maintained at that level during bulb dormancy. 
Figure 1: The two major gamma-glutamyl peptides in onion. 
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γ−Glutamyl (trans)peptidase, which is active in leaves, roots and bulbs of growing onion, 
transfers the γ−glutamyl group of the gamma-glutamyl peptides to amino acids or other 
peptides, leading to S-alk(en)yl-cysteine sulphoxides as product. After tissue disruption and 
mixture of the vacuole and cytoplasmic contents, enzymatic hydrolysis cleaves these 
compounds to pyruvate, ammonia and a thiosulfinate [Rose 2005]. Thiosulfinates are 
intermediates in the formation of sulphur volatiles [Freeman 1976] and thus responsible for 
the typical flavour [Block 1992]. They differ among the species according to their content of 
the enzyme alliinase and S-alk(en)yl-cysteine sulphoxide precursors [Lanzotti 2006]. 
The major and characteristic S-alk(en)yl-cysteine sulphoxide in intact onion is trans-1-
propenyl-cysteine sulfoxide (isoalliin). By the influence of the enzymes alliinase and/or 
lachrymatory synthase it gives rise to sulfenic acids which react to thiosulfinates, cepaenes, 
zwiebelanes and the lachrymatory factor 1-propanethial S-oxide (Figure 2). 
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Figure 2: Formation of lachrymatory factor, zwiebelanes, cepaenes and thiosulfinates by alliinase and 
lachrymatory factor synthase 
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Further important S-alk(en)yl-cysteine sulphoxides found in onion and related species are 
S-propyl-cysteine sulfoxide (propiin), S-methyl-cysteine sulfoxide (methiin) as well as 
S-allyl-cysteine sulphoxide (alliin), a characteristic constituent of garlic [Jones 2004] (Figure 
3).  
Figure 3: Flavour precursors of the genus Allium 
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Flavour intensity depends on genetic factors and environmental conditions such as sulphur 
and nitrogen levels in the soil [Randle 1992, Randle 2000, Randle 1994], growing 
temperatures [Coolong 2003] and irrigation conditions [Freeman 1973].  
Analysis of onion compounds has been reviewed in detail by Lanzotti [Lanzotti 2006]. It is 
performed using gas chromatography - mass spectrometry (GC-MS), liquid 
chromatography - mass spectrometry (LC-MS), nuclear magnetic resonance spectroscopy 
(NMR), supercritical fluid extraction – mass spectrometry, supercritical fluid extraction - gas 
chromatography - mass spectrometry, supercritical fluid extraction - liquid chromatography - 
mass spectrometry, gas chromatography - atomic emission spectroscopy, spectral 
photometric methods and liquid chromatography - diode array detection (LC-DAD). 
Problems, when using these methods, may occur because of the release and activity of the 
above mentioned enzymes during material preparation, because this might change the 
composition of the material to be analysed. 
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Saponins 
Another class of bioactive compounds present in onion are saponins, namely sitosterol, 
gitogenin, oleanolic acid, amayrin, diosgenin, saponin beta-chlorogenin, cepagenin, 
alliospirosides A-D, alliofuroside A, tropeosides A1/A2 and tropeosides B1/B2, ascalocosides 
A1/A2 and ascalonicoside B [Lanzotti 2006].  
Flavonoids 
Onions are rich in flavonoids and phenolics. Major flavonoids in onion are quercetin and its 
glycosides, isorhamnetin and glycosides, rutin and kaempferol [Lanzotti 2006]. 
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5.2 Bone 
5.2.1 Function, structure and composition of bone 
The skeleton, which consists of bone and cartilage, has several functions: it protects the 
internal organs such as heart, brain or the spinal cord and ensures the mechanical stability of 
the body. Bones are levers for muscles and thus support locomotion. They play an important 
role in the maintenance of mineral homeostasis as they serve as an ion reservoir, especially 
for calcium and phosphate. Bone has an influence on the acid-base-balance, because it 
absorbs or releases alkaline salts in cases of excessive blood pH changes.  
The skeleton consists of two, anatomically different types of bone: cortical (or compact) bone 
and cancellous (or spongy or trabecular) bone. Cortical bone has mainly protective functions 
and is composed of 80 to 90 % of calcified tissue surrounding the cancellous bone as a thick, 
dense layer. Cancellous bone consists of a honeycomb-like network of thin trabeculae and is 
found in vertebrae and in the epiphysis of long bones. 15 to 25 % of cancellous bone is 
calcified and due to its structure, it provides stability to withstand mechanical load, but it also 
performs metabolic functions. Both cortical and trabecular bone surrounds the bone marrow 
stroma which contains precursor cells of bone-forming osteoblasts and bone-resorbing OCs. 
Bone consists of water (5 - 10 %), organic matrix (20 – 40 %) and minerals (50 – 70 %), 
which surround the cells. The organic matrix of bone, mainly responsible for the elasticity and 
flexibility of bone, consists of collagen fibres, predominately type I, and non-collagenous 
proteins which make up to 15 % of the total protein content. Non-collagenous proteins are 
synthesised by bone forming cells and can be cleaved into proteogylcans, glycosylated 
proteins or gamma-carboxylated proteins. The role of these proteins is not yet well defined. 
Many of them seem to be multifunctional: they might be involved in the control of osteoclastic 
and osteoblastic metabolism and in the regulation of bone matrix mineralisation. The bone 
minerals are found on the collagen fibres in a form similar to the geological hydroxyapatite 
[Ca10(PO4)6(OH)2]. This hydroxyapatite is less crystalline and contains some “defects”, for 
example missing hydroxide ions, or impurities like carbonate or magnesium. Thus, bone 
serves as an ideal reservoir for calcium, phosphate and magnesium ions. In addition, the 
minerals provide mechanical rigidity and load bearing strength to the bone. 
The anatomy and function of bone has been reviewed in detail by Dempster et al. and Baron 
[Baron 1999, Dempster 2006]. 
5.2.2 Bone cells 
The principal cells of bone belong to the OC lineage or osteoblast lineage. OCs are derived 
from haematopoietic stem cells and they are the exclusive bone resorbing cells. The cells 
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that contribute to bone formation are derived from mesenchymal stem cells and are named 
osteoblasts, osteocytes and bone lining cells. Osteoblasts synthesise the bone matrix, 
osteocytes are embedded into the mineralised bone and bone lining cells cover the bone 
surface. 
Osteoclasts (OCs) 
OCs are multinucleated, bone resorpting giant cells which derive from cells of the 
monocyte/macrophage lineage under the influence of specific growth factors. They are in 
direct contact with the calcified bone surface via the OC’s clear zone which surrounds the 
ruffled border. It is the location where bone resorption occurs (Figure 4). 
Figure 4: Mechanisms of the resorption activity of an OC (courtesy of Prof. W. Hofstetter) 
 
 
During the resorption process OC attach to bone. This cell-surface adhesion is mediated by 
integrin receptors [Nakamura 2007]. The OC becomes polarised; fibrillar actin in the 
cytoskeleton rearranges and forms a belt-like structure, the actin-ring, which is visible after 
specific staining. In addition, a tight junction between bone and osteoclastic membrane, the 
sealing zone, is formed which isolates the extracellular bone-resorbing compartment [Boyle 
2003]. If the osteoclastic activity is disturbed, for example by inhibitors like calcitonin, 
structural anomalies of the actin ring may be observed [Suzuki 1996, Vaananen 2000]. The 
ruffled border, which is surrounded by the clear zone, includes infoldings of the membrane to 
increase the cell’s surface area. Through this ruffled border, protons are excreted by the OC 
onto the bone surface. Protons, present in the cytosol of the OC, arise from molecules of 
carbon dioxide and water which react to carbonic acid under the catalysis of the enzyme 
carbonic anhydrase II. Proton transport to the bone matrix, mediated by a vacuolar 
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electrogenic proton pump (H+-ATPase), and chloride ion transport, mediated by a chloride 
channel, form an acid environment of pH ~ 4.5 [Teitelbaum 2003]. Thus, the hydroxyapatite 
crystals in the bone are dissolved after digestion of their links to collagen which is degraded 
by lysosomal enzymes. 
Lysosomal enzymes such as cathepsin K and tartrate resistant acid phosphatase, which are 
synthesised by OCs, are found in the endoplasmatic reticulum, golgi, and many vesicles. 
These acidified vesicles transport the enzymes to the apical pole of the OC where they fuse 
with the plasma membrane and thus form the ruffled border [Teitelbaum 1995]. Lysosomal 
enzymes are secreted through the ruffled border into the extra cellular bone-resorbing 
compartment by exocytosis. They degrade the bone matrix compounds and form lacunae 
because they are now at an optimal pH. Remaining residues of the resorption are either 
internalised by the OC, released from the clear zone in the extracellular bone-resorbing 
compartment or transported to the basolateral membrane and released. Intracellular 
hydrogen carbonate is exchanged through extracellular chloride through the basolateral 
membrane. These mechanisms avoid alkalinisation of the cell and provide efficient amounts 
of chloride for the ruffled-border chloride channels.  
OCs are derived from haematopoietic precursor cells. The two essential growth factors in this 
process are receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating 
factor (M-CSF) [Pixley 2004, Yasuda 1998]. At an early stage of osteoclastogenesis, c-Fms, 
the receptor for M-CSF, is expressed by haematopoietic stem cells and M-CSF induces the 
proliferation and survival of monocytic cells and the expression of RANK, the receptor for 
RANKL [Arai 1999]. Later, M-CSF, RANKL and other downstream effectors of RANK 
signalling lead to the commitment and differentiation of pre-OCs which fuse to multinucleated 
cells. M-CSF is also involved in the cytoskeletal rearrangement of the OC for bone resorption 
[Ross 2006]. Both, RANKL and M-CSF are produced by marrow stromal cells and 
osteoblasts [Suda 1999]. 
Osteoblasts and osteocytes 
The mature osteoblast is a cuboidal cell with a round nucleus at the base of the cell, huge 
Golgi-complex and well-developed rough endoplasmatic reticulum. Osteoblasts derive from 
mesenchymal stem cells (bone marrow stromal stem cells or connective tissue mesenchymal 
stem cells). The same cell line also gives rise to adipocytes, chondrocytes, fibroblasts and 
myoblasts. The mesenchymal stem cells which commit to the osteoblast lineage are called 
osteoprogenitors. Osteoprogenitors proliferate and differentiate to pre-osteoblasts and later 
to mature osteoblasts. Mature osteoblasts synthesise the bone matrix constituents including 
collagen, non-collagenous proteins, but also growth factors. At the end of this process, they 
become either osteocytes, lining cells or undergo apoptosis. Osteocytes are located in 
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lacunae of bone matrix. Originally they were osteoblasts which have become embedded by 
the bone matrix built by themselves. Osteocytes are connected with other osteocytes or 
lining cells via long cell processes in small channels called canaliculi and thus, form a 
network throughout the bone matrix. Bone lining cells are inactive osteoblasts covering all 
available bone surfaces. They provide a bone-blood barrier and regulate the flow of ions in 
and out of bone extracellular fluid. 
The morphology, maturation and functional activities of osteoblast lineage cells have been 
reviewed by Dempster et al. and Aubin et al. [Aubin 2006, Dempster 2006]. 
5.2.3 Bone remodelling 
Bone modelling is reshaping of bone characterised by an independent action of OCs and 
osteoblasts. This process affects size and shape of bone and occurs during growth for a 
period of about 18 years, or in adults during fracture healing for a period of about one year. 
In contrast to bone modelling, bone remodelling affects bone density, mineralisation and 
microstructure and it continues throughout the life. Bone deposition and bone resorption 
occur at the same spot and the action of OCs and osteoblast are coupled processes. 2 – 3 % 
of cortical bone and 25 % of cancellous bone are remodelled per year. Ideally, bone 
remodelling maintains the current amount of bone, but at the age of about 35, the amount of 
bone resorption exceeds the amount of bone formation resulting in a decline in bone mass. 
Bone remodelling takes place continuously at the bone surface, mainly at the endosteum and 
in the Haversian system in response to mechanical load, calcium homeostasis or repair of 
microfractures. It is accomplished by teams of OCs and osteoblasts, called basic multicellular 
units (BMU), and it follows an activation-resorption-formation sequence consisting of four 
stages: (I) resorption, (II) reversal phase, (III) formation, and (IV) resting phase. It is 
hypothesised that pre-osteoclasts attach to the bone surface after they have been activated 
by factors released by lining cells, osteocytes or marrow cells. They fuse to form OCs, which 
start resorption and thereby dig out a tunnel to create a “cutting cone” into the cortical bone 
or lacunae into cancellous bone. Afterwards, the OCs detach, and during the reversal phase, 
some macrophage-like cells cover the surface and form a line that cements together old and 
new bone. In the next step, the formation period, preosteoblasts are activated, then 
differentiate and proliferate to osteoblasts, which follow along the surface and lay down initial 
matrix (osteoid) in parallel layers in the closing cone. After a certain time the initial matrix 
becomes mineralised and osteoblasts become lineage cells.  
The process of bone remodelling has been reviewed by Baron and Dempster et al. [Baron 
1999, Dempster 2006]. 
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5.2.4 Osteoporosis 
Osteoporosis is a systemic disease of the skeletal system characterised by reduced bone 
mass and microarchitectural deterioration of bone tissue. The WHO defines osteoporosis as 
a bone mineral density or a bone mineral content, that is -2.5 standard deviations below the 
young adult mean (20-year-old healthy female average) for the population, measured by 
techniques such as dual-energy X-ray absorptiometry [World Health Organisation 1994]. In a 
healthy person, bone mass increases until the age of approximately 30 and afterwards, it 
gradually decreases. A low bone mineral density in an elderly person implies a suboptimal 
bone mass in young adolescence or increased bone loss in later life, or both [Prentice 2004]. 
Osteoporosis results in an increased bone fragility and increased risk of fractures 
[Consensus development conference 1993, Prentice 2004]. The fractures occur throughout 
the skeleton, mostly at the vertebrae, wrist and hip, and lead to an increased morbidity, 
disability, and mortality in elderly people [Bonjour 1997]. With the increase in life expectancy, 
fracture prevalence will even rise. In addition to the individual burden, fractures impose 
enormous costs for health systems worldwide [Harvey 2006, Johnell 1997, Schwenkglenks 
2004].  
Most pharmacological treatments of osteoporosis decrease the risk of fractures by retarding 
the decrease in bone mineral density either by stimulating bone formation or by decreasing 
bone resorption [Boyle 2003]. One drug stimulating bone formation is teriparatide, a 
recombinant form of human parathyroid hormone 1-34. Bisphosphonates, estrogen and 
selective estrogen receptor modulators serve as antiresorptive treatment [Harada 2003], and 
calcium as well as vitamin D play an important role as a co-therapy [Dawson-Hughes 2006, 
Heaney 2006, Roux 2008].  
However, due to the side effects and costs of these medications, prevention of osteoporosis 
and its consequences is preferable. A nutritional approach may thereby play a promising 
role. Various studies have demonstrated, that an increased intake of vegetables and fruits 
could positively influence the balance between bone formation and bone resorption [Putnam 
2007], and that it is related to a higher bone mineral density [McGartland 2004, New 2000, 
Prynne 2006, Tucker 2002, Tucker 1999]. It was postulated that this effect is due to the 
food’s base excess buffering metabolic acid [New 2000, Tucker 1999]. However, studies by 
Mühlbauer et al. have shown that the intake of several vegetables, fruits and herbs 
decreases bone resorption in rats [Muhlbauer 1999, Muhlbauer 2000, Muhlbauer 2003a, 
Muhlbauer 2003b], independently of their base excess, and the effect can be most likely 
attributed to pharmacological mechanisms [Muhlbauer 2002]. Onion was among the 
examined vegetables which were shown to inhibit bone resorption in vivo. Using a bioassay-
guided fractionation, GPCS was identified by Wetli et al. as the active substance in vitro 
[Wetli 2005]. 
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5.3 Analytical methods 
Chromatography coupled to spectrometry was used to analyse GPCS in biological matrices 
(plant, rat plasma). Due to the high polar character of GPCS the method of first choice was 
reverse-phase high-performance liquid chromatography with diode-array or mass 
spectrometric detection (RP-HPLC-DAD or -MS). These methods, as well as sample 
preparation by solid phase extraction (SPE) are subsequently briefly described and 
referenced.  
5.3.1 High-performance liquid chromatography (HPLC) 
HPLC is the most frequently applied technique in pharmaceutical analytics. It is a column 
chromatography under high pressure used to separate and fractionate mixtures of 
substances or substances present in various biological matrices. For detection, it is usually 
combined with spectroscopic techniques. 
A modern HPLC system is microprocessor-controlled, consists of a solvent reservoir, pumps, 
injection port, column with column oven, and detector. The solvent is pressed through the 
column by means of the pumps under high pressure. The sample mixture is dissolved in the 
mobile phase and each compound interacts with the stationary phase which is present in the 
column. The amount of interaction depends on the sorbent of the stationary phase and on 
the solvent of the mobile phase. Compounds with a high affinity to the sorbent remain longer 
on it and show a higher retention time than compounds with a low affinity. The retention time 
is the time when the compound is eluted from the column. Chemical and physical 
mechanisms, which retain the compounds on the sorbent, base upon adsorption, distribution, 
chiral interactions, ion-pair interactions, size-exclusion or affinity. Therefore numerous 
sorbents are available on the market, which are used to achieve optimal separation of 
complex mixtures. Several detection principles are used in HPLC: ultraviolet-visible (UV-VIS) 
spectroscopy, fluorescence, evaporative light scattering, electrochemistry, electrical 
conductivity, NMR, MS and refractive index. 
HPLC is reviewed in [Luque-Garcia 2007, Rücker 2001]. 
High-performance liquid chromatography - Diode array detection 
(HPLC-DAD) 
Diode array detectors are widely used for the identification and quantitation of analytes. They 
allow simultaneous measurement of UV, VIS and near-infrared light absorption. The resulting 
spectra can then be compared to an online/offline database. As the absorption correlates 
with the concentration of the analyte, the signal can be used for quantitation. 
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A schematic view of an optical system of a diode array detector is given in Figure 5. In a 
diode array detector, a deuterium or holmium lamp emits light over the UV wavelength range, 
and a tungsten lamp emits light over the visible and near-infrared wavelength range. The 
light of the lamps is focussed by the achromat through the flow cell onto a holographic 
grating. The dispersed light from the grating falls onto a diode array which contains hundreds 
of individual photodiodes. The output of each diode is recorded by a computer. When the 
diode array detector is coupled with HPLC and a substance is eluted through the sensor cell, 
the information acquired by the diodes can either be used to obtain an absorption spectrum 
or, by selecting the appropriate diode, to obtain a chromatogram at a specific wavelength, 
usually at the maximum absorption of the analyte.  
Sample analysis by HPLC-DAD is reviewed by Rücker et al. and Pragst et al. [Pragst 2004, 
Rücker 2001]. 
Figure 5: Schematic view of on optical system of a diode array detector (courtesy of D. Mabboux) 
 
High-performance liquid chromatography - mass spectrometry 
(HPLC-MS) 
Mass spectrometry analyses the mass to charge (m/z) ratio of ions. A typical mass 
spectrometry instrument consists of an ion source, a mass analyser and a detector. Two 
modes of sample introduction are used: samples are either infused directly into the source 
(method of choice to optimise the compound detection), or a HPLC system is attached to the 
source.  
In our experiments, a HPLC system was coupled to a triple quadrupole mass spectrometer 
(QQQ) with an electrospray ionisation (ESI) source. The ESI source produces charged ions 
of the analytes in the liquid phase by pumping liquid through a small, charged metal capillary 
and producing an aerosol containing small sized droplets of 1-10 µm (Figure 6). Uncharged 
gases, like nitrogen, usually support the nebulising process, help to evaporate the solvent in 
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the droplets, and prevent the ions from being neutralised. The transition of the ions to the 
mass analyser is performed by a vacuum interface. A quadrupole mass analyser consists of 
four parallel metal rods which are arranged in a square. The opposing rod pairs are 
connected together electrically, and a direct current voltage is impressed to generate 
electrical fields. Ions travel down the rods and are filtered depending on particular 
magnitudes and frequencies in a way that only ions with a special characteristic m/z ratio 
reach the detector. Other ions oscillate and are neutralised by collision with the rods. Masses 
of all ions can be scanned by consistently altering the electric fields to give a mass spectrum. 
To improve sensitivity or to obtain structural information, mass analysers are used in series, 
like QQQ. The first and third quadrupole act as mass filters whereas the second is used as 
collision cell. Parent ions which were filtered or isolated from the first quadrupole are 
collisionally dissociated by the second quadrupole and its fragments are analysed by the 
third quadrupole. Finally, a detector counts the electrons generated from the ions and data 
are presented as a mass spectrum which contains a specific pattern of ion fragments of each 
analyte. 
Mass spectrometry and its use in the quantification of peptides in biological systems is 
reviewed in [Bantscheff 2007, Price 1991, Rücker 2001, Squires 1998]. 
Figure 6: Schematic view of an electrospray ionisation process (courtesy of D. Mabboux) 
 
5.3.2 Solid phase extraction (SPE) 
Sample preparation is a very important part of the analysis of substances in biological 
matrices. Its two main aims are the purification of the analyte from interfering matrix 
compounds (clean-up) and the concentration of the analyte. 
A widely used, economic, fast and effective method for sample preparation is SPE. The 
separation principle is based on interactions between analyte, matrix and a sorbent. 
Common sample extraction products consist of a cartridge-like column or a 96-well-plate 
filled with a sorbent.  
SPE usually consists of four steps. First, the sorbent is conditioned with a solvent to remove 
impurities of the sorbent and to increase separation reproducibility (“Conditioning”). In the 
second step the sample is loaded on the solid phase and the analyte is enriched on the 
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sorbent (“Sampling”). Afterwards, undesired matrix compounds are removed by washing the 
sorbent with a solvent which does not displace the analyte (“Washing”). Finally, the analyte is 
eluted (“Elution”) (Figure 7).  
Figure 7: Schematic view of the several steps of SPE (courtesy of D. Mabboux) 
 
 
The extraction process can be automated using robotic systems, like ASPEC (Figure 8). 
Even steps prior or following SPE, like serial dilution of standards, addition of internal 
standards, derivatisation or injection onto HPLC could be performed by these systems. Thus, 
throughput and reproducibility are increased, and the exposure of personal with hazardous 
materials is minimised. Several sorbents are available: they can be polymeric, silica-based, 
carbons or mixed and separate by non-polar, polar and/or ionic interactions with the analyte. 
Sample preparation by SPE is reviewed in [Brochure: Solid Phase Extraction 2006, 
Fontanals 2007, Hennion 1999, Poole 2000, Smith 2003]. 
Figure 8: SPE Robotic system 
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6.1 Materials and methods 
This section describes the materials and methods, which were used to determine GPCS in 
onions and various other plants. 
6.1.1 Quantitation of GPCS using HPLC-DAD 
Standards, solvents and chemicals 
As GPCS was not commercially available it was isolated as described in  chapter 7 Part II: 
Isolation of GPCS from Allium cepa L. and synthesis of GPCS. 
Bidistilled water was prepared in house. N-(L-α-Aspartyl)-L-phenylalanine methyl ester 
(aspartame), acetonitrile Chromasolv®, methanol Chromasolv® and ortho phosporic acid 
85 % extra pur were purchased at Sigma-Aldrich2 and Merck. Round filters were obtained 
from Schleicher & Schuell and 0.45-µm filters from Infochroma. 
Plant material 
Onions, garlic, leek, wood garlic, plum, red wine, crimp parsley, plain parsley, dill, sage, 
chinese cabbage, broccoli, rocket, smallage, common bean, red cabbage, cucumber, 
mushroom, tomato, lettuce, rosemary, thyme, boletus, fennel and orange were purchased on 
the local food market in Bern and either lyophilised or dried, subsequently pulverised, and 
stored at -20°C until use. 
Instrumentation 
The HPLC system consisted of an Agilent 1100 Series degasser, capillary pump, diode array 
detector, thermostated column compartment, thermostated autosampler and an HP 
computer with ChemStation for LC 30 Rev. A. 09.03 [1417] (Agilent 1990-2002) software. 
                                               
2
 A list of the addresses of suppliers is given in section 11.2 Appendix 2: List of suppliers. 
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Chromatographic conditions 
The chromatographic conditions are shown in Table 1. 
Table 1: Chromatographic conditions for quantitation of GPCS using HPLC-DAD 
Stationary Phase: 125 x 4 mm i.d. column, packed with Spherisorb ODS-1, particle size 3.0 µm 
and a 8 x 4 mm i.d. precolumn, packed with the same column material 
(Machery-Nagel) 
Mobile Phase: Solvent A: Water containing 0.05 % phosphoric acid 85 % (v/v) 
Solvent B: Acetonitrile containing 0.05 % phosphoric acid 85 % (v/v) 
75 % B, isocratic elution 
Run time: 15 min 
Flow: 0.7 ml/min 
Temperature: 40°C 
Detection: Wavelength for the quantitation of GPCS with or without the internal standard 
method (aspartame as internal standard (I.S.)): UV 195 ± 4 nm, online 
recording of the UV spectra from 190 - 400 nm (DAD). 
Validation 
Peak identification (selectivity/specificity) 
Chromatographic selectivity: The retention time of the analyte and the I.S. were assigned 
with the corresponding standards. 
Spectroscopic selectivity: The DAD UV spectra in the range of 190 – 400 nm were compared 
to the spectra of the standards. The recorded spectra were also used for the peak purity 
check. 
Calibration and linear range 
The calibration of GPCS was performed using the I.S. and linear regression analysis over the 
concentration ranges of 10 µg/ml to 200 µg/ml with 36 µg/ml of I.S.. To obtain the calibration 
graph, the area ratio of GPCS to I.S. was plotted against the concentration of GPCS. 
Five calibrator concentrations of 10, 50, 100, 150, and 200 µg/ml GPCS and 36 µg/ml I.S. 
were prepared in methanol/water/formic acid (50/50/0.05; v/v) from stock solutions of GPCS 
(1 mg/ml) and I.S.. Each sample was measured three times. 
Intra- and interday precision and accuracy of the calibration 
The intraday precision was determined measuring the samples for each concentration (30, 
120, 180 µg/ml) five times within the same day.  
The interday precision was established measuring the three control samples (30, 120, 
180 µg/ml) nine times over a period of one month. 
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Mean, standard deviation (s.d.), relative standard deviation (r.s.d.) as well as accuracy were 
calculated. The control samples were tightly sealed and stored at –20°C when not in use. 
Limit of quantitation (LOQ) 
The LOQ was defined at the concentration where the peaks could be clearly integrated with 
a signal to noise ratio of 10 to 1.  
Determination of GPCS in plant material 
Sample preparation 
1.0 g of dry plant powder was accurately weighed. It was extracted with 50.0 ml of 
methanol/water/formic acid (50/50/0.05; v/v/v) with or without 36 µg/ml I.S. at room 
temperature using an ultrasonic bath for 5 min (modified method based on [Wetli 2005]). 
Then, the suspension was filtered through a 595 grade round filter and through a 0.45-µm 
filter. 7 or 10 µl were injected into the HPLC. 
Intra- and interday precision and accuracy of the extraction 
For the determination of the intraday precision, five extracts were prepared and analysed six 
times each using HPLC. 
For the determination of the interday precision, fifteen extracts were prepared over a period 
of one month. Each sample was analysed six times using HPLC.  
Mean, s.d. and r.s.d. were calculated. The control samples were tightly sealed and stored at 
–20°C when not in use. 
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6.2 Results 
In this chapter, the results of the determination of GPCS in various plant materials and of the 
validation of the HPLC method, are described. 
6.2.1 Validation of HPLC-DAD method 
Peak identification 
The retention time for GPCS and I.S. was 5.8 min (range: 5.6 – 6.0 min) and 10.9 min 
(range: 10.7 - 11.1 min), respectively. The blank run showed no interferences with GPCS 
and I.S.. 
Calibration and linearity 
The calibration was linear at the concentration range from 10 to 200 µg/ml. The linearity data 
are summarised in Table 2. 
Table 2: Calibration data for the quantitation of GPCS obtained by performing triplicates for each of the 5 
concentration levels (10, 50, 100, 150 and 200 µg/ml) 
Analyte Retention time 
[min] 
m1) b1) Correlation coefficient r 
GPCS 5.8 1.1222 – 0.0136 0.9993 
1)y=mx + b; x: amount of GPCS; y: ratio of the areas under the peak GPCS:I.S. 
Intra- and interday precision and accuracy of the calibration 
The intraday precision at low, medium and high concentration levels was ≤ 0.2 %. The 
accuracy of the assay (± % of the target concentration added) ranged from -2.1 to +1.9 
(Table 3). 
Table 3: Intraday precision and accuracy for the quantitation of GPCS (control samples) 
Added GPCS 
[µg/ml] 
Found 
[Mean, µg/ml] 
s.d. 
[µg/ml, n=5] 
Precision 
[% r.s.d., n=5] 
Accuracy 
[%] 
30 30.6 0.36 0.1 -2.1 
120 117.7 2.73 0.2 1.9 
180 178.4 2.29 0.1 0.9 
 
The interday precision at low, medium and high concentration levels was ≤ 0.9 % and the 
assay accuracy ranged from -1.8 to +2.8 % (Table 4). 
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Table 4: Interday precision and accuracy for the quantitation of GPCS (control samples) 
Added GPCS 
[µg/ml] 
Found 
[Mean µg/ml] 
s.d. 
[µg/ml, n=9] 
Precision 
[% r.s.d., n=9] 
Accuracy 
[%] 
30 30.9 0.26 0.9 2.8 
120 117.8 0.61 0.5 -1.8 
180 179.1 0.62 0.4 -0.5 
Limit of quantitation (LOQ) 
The LOQ corresponded to the lowest calibrator, i.e.10 µg/ml. 
6.2.2 Determination of GPCS in plant material 
To examine the concentration of GPCS in onion, lyophilised onion powder was extracted with 
methanol-water-formic acid containing aspartame, which was used as I.S. (Figure 9). 
Figure 9: Structures of GPCS and aspartame 
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Validation of GPCS extraction from onion 
Peak identification 
The retention time for GPCS and I.S. was 5.9 min (range: 5.6 – 6.0 min) and 8.7 min 
(range: 8.2 - 9.1 min), respectively. The DAD UV spectra were identical to the corresponding 
standards and peak purity results confirmed that the GPCS and I.S. peaks were 
homogeneous and pure in the analysed samples. 
Intra- and interday precision of the extraction of GPCS from onion 
For the extraction of GPCS from dry onion powder the intraday precision was 2.38 % 
(Table 5). 
Table 5: Intraday precision for the quantitation of GPCS in onion powder (extraction 
samples) 
GPCS/onion powder 
[mg/g] 
s.d. 
[mg/g, n=5] 
Precision  
[% r.s.d., n=5] 
4.27 0.10 2.38 
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The interday precision for the extraction of GPCS from dry onion powder was 3.64 % 
(Table 6). 
Table 6: Interday precision for the quantitation of GPCS in onion powder 
(extraction samples) 
GPCS/onion powder 
[mg/g] 
s.d. 
[mg/g, n=15] 
Precision 
[% r.s.d., n=15] 
4.20 0.15 3.64 
Screening of different varieties of onion according to the concentration 
of GPCS 
Several varieties of onion were tested to determine their content of GPCS. Zero to 21 mg 
GPCS per g powder of onion were measured (Table 7). 
Table 7: Content of GPCS in several varieties of onion 
Variety GPCS/onion powder 
[mg/g] 
White onion 21 
Red onion 0 
Small shallot 1 
Shallot sample I 7 
Shallot sample II 1 
Green onion 0 
Screening of other plants concerning the presence of GPCS 
As dry powders of garlic, leek, wild garlic, plum, red wine, crimp parsley, plain parsley, dill, 
sage, chinese cabbage, broccoli, arugula, celeriac, french bean, red cabbage, cucumber, 
field agaric mushroom, tomato, lettuce, rosemary, thyme, yellow boletus, fennel, and orange 
showed an inhibition of bone resorption in rats [Muhlbauer 1999, Muhlbauer 2003b] these 
plants were screened regarding the presence of GPCS. GPCS could not be found in any of 
these food or beverage samples. 
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6.3 Discussion 
To screen onions and various other bone-resorption inhibiting plants regarding the presence 
of GPCS, a method for fast, routine, quantitative analysis of GPCS using HPLC-DAD was 
established. Gamma−glutamyl peptides have been examined previously using various 
methods using 35S-sulphate, amino acid analyser, two-dimensional electrophoresis or 
chromatography [Breu 1996]. GPCS has first been detected by Virtanen et al. [Virtanen 
1961a, Virtanen 1961b]. Methods to quantify GPCS in onions have been described by 
several authors [Coolong 2003, Kopsell 1999, Lancaster 1991, Lawson 1991, Matikkala 
1967, Shaw 1989, Wetli 2005]. The method developed for our study is an improvement of the 
one described by Wetli et al. [Wetli 2005]. Less time is needed for sample preparation, 
because SPE and freeze-drying prior to analysis by HPLC-DAD could be omitted. The use of 
an I.S. results in higher accuracy: aspartame was found to be a suitable candidate. This 
dipeptide derivative is structurally similar to GPCS, and therefore, it showed similar extraction 
and elution properties. Furthermore, aspartame is not biogenic, of synthetic origin, and 
commercially easily available. An effective extraction was obtained by using a mixture of 
methanol/water/formic acid as extracting agent and sonication, avoiding the enzymatic 
cleavage of the target compound and thus stabilising the extract [Mütsch-Eckner 1992]. 
Chromatography was performed using a column filled with non end-capped octadecylsilyl 
material and a mobile phase consisting of (A) water containing 0.05 % phosphoric acid 85 % 
(v/v) and (B) acetonitrile containing 0.05 % phosphoric acid 85 % (v/v). Due to the lack of 
chromophores, detection had to be performed at 195 nm, where GPCS exhibits an UV 
absorption maximum which can be attributed to the npi∗ transition of the two carboxyl 
groups [Pretsch 2001]. The mobile phase used in the experiments shows a UV 
cutoff < 195 nm and therefore, detection was possible near the UV cutoff of the DAD. The 
developed extraction and chromatographic conditions were fully validated. The method was 
proved to be sufficiently reproducible with an intraday variability of 4.3 ± 2.4 % (mean ± r.s.d) 
and an interday variability of 4.2 ± 3.6 %. The linear regression of the calibration showed a 
good correlation coefficient (r = 0.9993) and the LOQ was set at 100 ng allowing reliable 
determination of GPCS in plant material (signal to noise ratio of 10 to 1).  
After having validated the method, the plant samples were analysed. The content of GPCS in 
lyophilised onion powder ranged from 0 to 21 mg per g onion powder. These results 
correspond to the findings of others who measured GPCS in concentrations from 0 to 25 mg 
per g [Coolong 2003, Kopsell 1999, Lancaster 1991, Lawson 1991, Matikkala 1967, Shaw 
1989]. In the onion, GPCS functions as sulphur and nitrogen storage [Kasai 1980] and as an 
intermediate in the biosynthetic pathway of flavour precursors [Lancaster 1989, Lancaster 
1991]. Variation in the concentration of GPCS was shown to depend on selenium content of 
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the soil [Kopsell 1999] and growing temperature [Coolong 2003]. Other factors which most 
probably affect GPCS concentration in onions are sulphur and nitrogen content of the soil 
and irrigation conditions. These have been shown to influence the formation of onion flavour 
precursors [Block 1992, Freeman 1973, Randle 2000, Randle 1994].  
Gamma-glutamyl peptides are widely distributed over the plant kingdom. However, a 
systematic division or classification of these compounds according to their occurrence seems 
to be impossible [Kasai 1980]. A number of γ-glutamyl derivatives have been found in the 
genus Allium, but neither garlic (Allium sativum L.), nor leek (Allium ampeloprasum var. 
porrum L.) and wild garlic (Allium ursinum L.) were reported to contain GPCS, which 
corresponds to the results obtained in our study. GPCS was also not detectable in other 
tested plants from different families, namely plum (Prunus L.), red wine, crimp parsley 
(Petroselinum crispum Mill.), plain parsley (Petroselinum crispum var. neapolitanum Mill.), dill 
(Anethum graveolens L.), sage (Salvia L.), chinese cabbage (Brassica rapa ssp. Pekinensis), 
broccoli (Brassica oleracea var. silvestris L.), arugula (Eruca sativa Mill.), celeriac (Apium L.), 
french bean (Diplotaxis tenuifolia L.), red cabbage (Brassica oleracea var. capitata f. rubra 
L.), cucumber (Cucumis sativus L.), field agaric mushroom (Agaricus hortensis), tomato 
(Solanum lycopersicum L.), lettuce (Lactuca sativa L.), rosemary (Rosmarinus officinalis L.), 
thyme (Thymus L.), yellow boletus (Boletus edulis), fennel (Foeniculum vulgare Mill.) and 
orange (Citrus sinensis L.). These findings are consistent with the literature: GPCS has not 
been reported to be present in any other plants than onion and sandal (Santalum album L.) 
[Kasai 1980, Kuttan 1974].  
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7 Part II: Isolation of GPCS from Allium cepa L. and 
synthesis of GPCS 
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7.1 Retrosynthetic analysis of GPCS 
We envisaged that GPCS (1) could be synthesised from trans-S-(1-propenyl)-L-cysteine 
sulfoxide (2) by coupling with Boc-L-glutamyl-α-t-butyl-N-oxo-succinimide ester. Trans-S-(1-
propenyl)-L-cysteine sulfoxide (2) can be prepared by using two different methods.  
The first method implies the synthesis of 2 starting from L-cysteine (3). Coupling with 
allylbromide [Lawson 1991], followed by isomerisation and oxidation leads to a cis/trans 
mixture of 2 [Carson 1966].  
The second method starts from L-cysteine ethyl ester (4) using a Pd-catalysed C-S coupling 
as key step. The direct coupling with (cis)-1-bromoprop-1-ene circumvents the formation of 
the trans-isomer of 2 (Figure 10) [Namyslo 2006]. 
Figure 10: Retrosynthetic analysis of GPCS (1) 
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7.2 Materials and methods 
7.2.1 Isolation of GPCS from Allium cepa L. 
Plant material 
Onions were purchased on the local food market in Bern and lyophilised, subsequently 
pulverised, and stored at -20°C until use. 
Chromatographic conditions 
A method based on prior experiments of Wetli et al. [Wetli 2005] was used to isolate GPCS 
from onion.  
200 g of lyophilised onion were extracted with 1 l of ethanol (15 %, v/v) under stirring at 60°C 
for 1 h. The suspension was filtered through a towel and a 595 grade round filter. The 
residue was extracted again using the procedure mentioned above. The filtrates from both 
extractions were collected and after evaporation of the ethanol, the aqueous residue was 
lyophilised and stored at -20°C until use.  
About 12-g aliquots of the onion extract was dissolved in 100 ml of water and sonicated for 
5 min. Separation was performed using cationic exchange column chromatography as 
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described in Table 8. The fractions were monitored by thin layer chromatography (TLC) on 
silica gel 60 F254 with n-butanol/ethanol/acetic acid/water (25/30/10/10, v/v/v/v) as mobile 
phase and ninhydrin reagent (1 g of ninhydrin dissolved in 475 ml of isopropanol and 25 ml 
of acetic acid) for detection. In addition, fractions were checked by HPLC-DAD using the 
method described in section 6.1.1 Quantitation of GPCS using HPLC-DAD.  
Table 8: Conditions of cationic exchange chromatography 
Stationary Phase: 43 cm x 30 mm i.d. column (Kuhn AG) packed with 75 ml of Dowex 50 WX8, 
100 - 200 mesh (Sigma-Aldrich) 
Resin regeneration: 750 ml hydrochloric acid 6 % 
Resin wash: 1000 ml water 
Mobile Phase: 1. 1000 ml water  
2. 2 x 1000 ml 0.75 M ammonia 
Flow: ~ 15 ml/min 
Fraction collection: 250-ml cationic fractions were collected manually 
 
Fractions containing GPCS were pooled, evaporated and lyophilised. 2 – 3-g aliquots of this 
material, dissolved in 20 ml of 0.05 M acetic acid, were used for further separation with 
anionic exchange column chromatography shown in Table 9. Fractions were monitored using 
TLC as described above; equal fractions were pooled and lyophilised prior to HPLC-DAD 
analysis with the procedure mentioned above.  
Table 9: Conditions of anionic exchange chromatography 
Stationary Phase: 40 cm x 26 mm i.d. column (Amersham Bioscience GmbH) packed with 
50 ml of Dowex 1X8, 200 - 400 mesh (Sigma-Aldrich) 
Resin regeneration: 500 ml NaOH 4 % 
Resin activation: 2000 ml 2.5 M sodium acetate 
Mobile Phase: 1. 250 ml 0.05 M acetic acid 
2. 250 ml 0.5 M acetic acid 
3. 250 ml 2 M acetic acid 
Flow: ~ 2.5 ml/min 
Fraction collection: 12.5 ml fractions were collected using a fraction collector 684 (Büchi) 
Pump: Minipuls 3 peristaltic pump (Gilson) 
 
100-mg aliquots of the GPCS-containing material obtained by anionic exchange 
chromatography were separated by normal-phase medium pressure liquid chromatography 
(MPLC) as shown in Table 10. Fractions were monitored as described above and equal 
fractions were pooled. The ethanol was evaporated from fractions containing GPCS, and the 
aqueous residue was lyophilised prior to a final check using NMR. 
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Table 10: Conditions of normal-phase MPLC 
Stationary Phase: 22 cm x 25 mm i.d. column (Büchi) packed with silica gel 60, 15 - 40 µm 
particle size (Merck) and a 13 cm x 10 mm i.d. pre-column filled with the 
same material 
Mobile Phase: 1. 400 ml ethanol (75 %; v/v) 
2. 200 ml ethanol (wash) 
Flow: 1 - 2 ml/min 
Fraction collection: 60 fractions of 5 ml each were collected using a fraction collector 684 
(Büchi) 
Pump: chromatographic pump 681 (Büchi) 
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7.2.2 Synthesis of GPCS 
Solvents and chemicals 
Chemicals were purchased from Sigma-Aldrich or Merck and used without further 
purification. Solvents were of technical grade and distilled prior to use. 
Instrumentation 
Melting points (MP) were determined on a Büchi Melting point B-545 apparatus and were not 
corrected. 
NMR spectra were measured on a Bruker Advance 300 spectrometer, which operated at 
300 MHz for 1H and 75 MHz for 13C nuclei at 22°C. Chemical shift data are reported in units 
of δ (ppm) using as the internal standard either residual water (δ = 4.72 for 1H NMR), DMSO 
(δ = 2.50 for 1H NMR) or trichloromethane (δ = 7.27 for 1H-NMR spectra and δ = 77.0 for 
13C NMR spectra). Multiplicities are given as singlet (s), doublet (d), triplet (t), quartet (q), 
multiplet (m), and broad (br) for 1H NMR spectra and quartenary (q), tertiary (t), 
secondary (s) and primary (p) for 13C NMR spectra. Coupling constants (J) are reported in 
Hz.  
Infrared spectra were recorded on a Jasco FT-IR-460 Plus spectrometer equipped with a 
Specac MKII Golden Gate Single Reflection Diamond ATR System in the 400-4000 cm-1 
range and are reported in wave numbers (cm-1). 
Low and high-resolution mass spectra were recorded on a Waters Micromass Autospec Q 
mass spectrometer in electron impact mode at 70 eV. 
Reactions were monitored by thin layer chromatography on plates coated with silica gel 60 
with fluorescent indicator 254 nm (Merck). Substance spots were visualized by UV254 light 
and detected with ninhydrin solution. To prepare the ninhydrin solution, 1 g of ninhydrin was 
dissolved in 475 ml of isopropanol and 25 ml of acetic acid. 
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S-allyl-L-cysteine (5) [Lawson 1991] 
S
NH2
OH
O
C6H11NO2S
161.22
 
L-Cysteine hydrochloride (3) (1.57 g, 10.0 mmol) was dissolved in 30 ml of absolute ethanol 
and converted to the sodium salt with sodium (0.69 g, 30 mmol). Allyl bromide (1.2 g, 
10.0 mmol) was added to the suspension and water was added dropwise until a clear 
solution was obtained. After 2 h of stirring, the solution was concentrated to 10 ml, acidified 
to pH 8.0 with 6 M hydrochloric acid and kept overnight at 5°C. The white precipitate was 
filtered, washed with absolute ethanol and dried under vacuo. The crude product was purified 
by recrystallisation from a mixture of ethanol and water to yield S-allyl-L-cysteine (5) (1.26 g, 
78 %) as white needles. 
 
MP: 208 – 210°C 
IR (Film): ν max [cm-1] = 3020-2870, 2590, 2120 (NH3+), 1576 (COO-), 
988 and 916 (allyl double bond) 
1H-NMR (300 MHz, D2O): δ [ppm] = 2.92 (dd, J = 14.9, 7.5 Hz, 1H, SCH), 3.05 (dd, 
J = 14.9, 4.3 Hz, 1H, SCH), 3.20 (d, J = 7.1 Hz, 2H, 
CH2CHCH2), 3.88 (dd, J = 7.4, 4.3 Hz, 1H, CHNH2), 5.16 -
 5.23 (m, 2H, CHCH2), 5.75 – 5.89 (m, 1H, CH) 
13C-NMR (75 MHz, D2O): δ [ppm] = 30.8 (CH2CHCH2), 33.9 (SCH2CH), 53.6 (CHN), 
118.4 (CH2CH), 133.6 (CH2CH), 172.9 (OC=O). 
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Trans, cis-S-(1-propenyl)-L-cysteine (6) [Carson 1966] 
S
NH2
OH
O
C6H11NO2S
161.22
S
NH2
OH
O
 
Potassium tert-butoxide (1.0 g, 8.9 mmol) was added to a suspension of S-allyl-L-
cysteine (5) (1.0 g, 6.2 mmol) in 60 ml of dimethyl sulfoxide (DMSO) under external cooling. 
The pale amber solution was then stirred for 3 days at room temperature. 130 ml of ice-water 
and 3.5 ml of glacial acetic acid were added under cooling. The resulting solution was 
passed through a column filled with Amberlite IR-120 (H+) and the amino acid was eluted 
with 130 ml of a 2 N ammonium hydroxide solution. Concentration of the eluate yielded a 
mixture of trans- and cis-S-(1-propenyl)-L-cysteine (6) as white crystals. After filtration, the 
solution was further concentrated, and thus a second crop was obtained. Recrystallisation of 
the material from aqueous ethanol yielded pure trans, cis-S-(1-propenyl)-L-cysteine (6) 
(600 mg, 60 %) in a ratio of 1 to 6 (trans to cis). 
 
IR (Film): ν max [cm-1] = 2950 (NH3+), 1580 (COO-), no absorption at 920 
(allyl double bond) 
1H-NMR (300 MHz, D2O): δ [ppm] = 1.68 (dd, J = 6.8, 1.5 Hz, 3H, CH3 cis), 1.70 – 1.73 
(m, 3H, CH3 trans), 3.03 (dd, J = 14.9, 8.1 Hz, 1H, SCH2 
trans), 3.18 – 3.26 (m, 1H, SCH2 trans), 3.16 (dd, J = 14.9, 
7.4 Hz, 1H, SCH2 cis), 3.27 (dd, J = 15.1, 4.3 Hz, 1H, SCH2 
cis), 3.90 (dd, J = 7.3, 4.1 Hz, 1H, CH2CH cis), 3.86 – 3.91 
(m, 1H, CH2CH trans), 5.79 (dq, J = 9.0, 6.6 Hz, 1H, CH3CH 
cis), 5.92 – 5.99 (m, 1H CH3CH trans, 1 H SCH trans) 
13C-NMR (75 MHz, D2O): δ [ppm] = 13.9 (CH3 cis), 17.7 (CH3 trans), 33.6 (SCH2 trans), 
33.9 (SCH2 cis), 53,7 (CHN cis), 54.2 (CHN trans), 120.0 
(CH=CHS trans), 122.6 (CH=CHS cis), 127.9 (CH3CH cis), 
132.2 (CH3CH trans), 172.5 (OC=O cis), 172.7 (OC=O trans) 
MS: [M+1]+ m/z 162.2 
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Trans, cis-(RS/SS)-diastereomers of S-(1-propenyl)-L-cysteine sulfoxide 
(2) [Carson 1966] 
S
NH2
OH
O
O
C6H11NO3S
177.22
S
NH2
OH
O
O
 
70 mg (0.4 mmol) of trans, cis-S-(1-propenyl)-L-cysteine (6) was suspended in 0.5 ml of a 
3 % aqueous hydrogen peroxide solution and was stirred for 24 h. The solvent was carefully 
removed in vacuo at 28°C, affording the product ( 2) (60 mg, 85 %) as a complex mixture of 
diastereomers. 
 
IR (Film): ν max [cm-1] = 2980, 2921 (NH3+), 1582 (COO-), 1010 (S=O), 
no absorption at 920 cm-1 (allyl double bond) 
MS: [M+1]+ m/z 178.4 
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N-Boc-L-cysteine ethyl ester (7) [Namyslo 2006] 
HS
NH
OEt
O
C10H19NO4S
249.33
Boc
 
Triethylamine (6.11 ml, 22.0 mmol) was added to a suspension of L-cysteine ethyl ester 
hydrochloride (4) (3.71 g, 20.0 mmol) and anhydrous tetrahydrofuran (25 ml) at 0°C. A 
solution of di-tert-butyl dicarbonate (4.80 g, 22.0 mmol) in 25 ml of anhydrous tetrahydrofuran 
was added in portions and the mixture was stirred at room temperature for 2 h. 40 ml of 
water was added to the solution and the solution was extracted with ethyl acetate (3x50 ml). 
The combined organic phases were washed with brine, dried over potassium sulphate and 
the solvent was removed under reduced pressure. The product was purified by flash column 
chromatography on silica gel (cyclohexane/ethyl acetate, 7/1, v/v) to give N-Boc-L-cysteine 
ethyl ester (7) (4.83 g, 97 %) as a white solid. 
 
1H NMR (300 MHz, CDCl3): δ = 1.29 (t, J = 7.1 Hz, 3H, CH3CH2), 1.45 (s, 9H, t-C4H9), 2.97 
(dd, J = 4.2, 4.2 Hz, 1 H, SCHa), 2.98 (dd, J = 4.2, 4.2 Hz, 
1 H, SCHb), 4.23 (q, J = 7.1 Hz, 2H, CH3CH2), 4.57 (ddd, J = 
7.8, 4.2, 4.2 Hz, 1 H, CHN), 5.42 (br d, J = 7.8 Hz, 1 H, NH) 
13C NMR (75 MHz, CDCl3): δ = 14.2 (CH3CH2), 27.4 (CH2S), 28.3 (OC(CH3)3), 54.8 
(CHN), 61.9 (CH3CH2), 80.2 (OC(CH3)3), 155.1 (NC=O), 
170.3 (OC=O) 
tert-Butyl (R)-2-[trans-prop-1-enylsulfanyl]-1-(ethoxycarbonyl) 
ethylcarbamate (8) [Namyslo 2006] 
S
NH
OEt
O
C13H23NO4S
289.39
Boc
 
Tris(dibenzyideneacetone)-dipalladium(0)-chloroform (Pd2(dba)3·CHCl3, 280 mg, 0.27 mmol), 
1,1’-bis(diphenylphosphino) ferrocene (499 mg, 0.90 mmol), trans-1-bromo-prop-1-ene 
(0.85 ml, 9.90 mmol) and anhydrous triethylamine (2.50 ml, 18.9 mmol) were added to 50 ml 
of anhydrous tetrahydrofuran and stirred at room temperature for 20 min and at 40°C for 
further 20 min. A solution of N-Boc-L-cysteine ethyl ester (7) (2.246 g, 9.01 mmol) in 
anhydrous tetrahydrofuran (2 ml) was added dropwise to the mixture and it was kept at 40°C 
for 4 h. After the addition of 50 ml of water and extraction with trichloromethane (3x50 ml), 
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the combined organic phases were dried over potassium sulphate and the solvent was 
evaporated in vacuo. The product was purified by flash column chromatography on silica gel 
(pentane/EtOAc, 7/1, v/v) to give pure tert-butyl (R)-2-[trans-prop-1-enylsulfanyl]-1-
(ethoxycarbonyl)ethylcarbamate (8) (2.0 g, 76 %) as a white solid.  
 
1H NMR (300 MHz, CDCl3): δ = 1.29 (t, J = 7.1 Hz, 3 H, CH3CH2), 1.45 (s, 9 H, t-C4H9), 
1.73 (dd, J = 6.4, 1.2 Hz, 3 H, CH3CH), 3.08 (d, J = 4.8 Hz, 
2 H, CH2S), 4.20 (q, J = 7.1 Hz, 2 H, CH3CH2), 4.54 (ddd, 
J = 7.8, 4.8, 4.4 Hz, 1 H, CHN), 5.36 (br d, J = 7.8 Hz, 1 H, 
NH), 5.77 (dq, J = 14.9, 6.4 Hz, 1 H, CH3CH), 5.86 (dq, 
J = 14.9, 1.2 Hz, 1 H, CH=CHS) 
(R)-2-tert-Butyloxycarbonylamino-3-[trans-prop-1-enylsulfanyl] 
propanoic acid (9) [Namyslo 2006] 
S
NH
OH
O
C11H19NO4S
261.34
Boc
 
tert-Butyl (R)-2-[trans-prop-1-enylsulfanyl]-1-(ethoxycarbonyl)ethylcarbamate (8) (563 mg, 
1.95 mmol) in anhydrous methanol (0.5 ml) was reacted with 1 M lithium hydroxide in 
methanol (3.89 ml) at 4°C for 12 h. Subsequently, 7  ml of DOWEX 50WX8 (H+) was added at 
the same temperature under stirring and filtered off. The filtrate was washed with ethyl 
acetate (3x50 ml). The aqueous layer was extracted with ethyl acetate (3x15 ml) and the 
combined organic layers were dried over potassium sulphate and evaporated in vacuo at 
28°C to yield (R)-2- tert-butyloxycarbonylamino-3-[trans-prop-1-enylsulfanyl]propanoic acid 
(9) (450 mg, 89 %)  
 
1H NMR (300 MHz, CDCl3): δ = 1.46 (s, 9 H, t-C4H9), 1.73 (dd, J = 6.4, 1.2 Hz, 3 H, 
CH3CH), 3.11 (d, J = 4.9 Hz, 2 H, CH2S), 4.59 (ddd, J = 7.7, 
4.9, 4.0 Hz, 1 H, CHN), 5.38 (br d, J = 7.7 Hz, 1H, NH), 5.81 
(dq, J = 14.8, 6.4 Hz, 1 H, CH3CH), 5.90 (dq, J = 14.8, 1.2 Hz, 
1 H, CH=CHS) 
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Trans-S-(1-propenyl)-L-cysteine (6) [Namyslo 2006] 
S
NH2
OH
O
C6H11NO2S
161.22
 
Trifluoroacetic acid (0.17 ml, 2.30 mmol) in anhydrous dichloromethane (0.17 ml) was added 
to (R)-2-tert-butyloxycarbonylamino-3-[trans-prop-1-enylsulfanyl]propanoic acid (9) (300 mg, 
1.15 mmol) and stirred for 20 h. Afterwards, 30 ml of water and 15 ml of activated 
Amberlyst A-21 were added in portions and stirred for 10 min. The ion exchange resin was 
filtered off, washed with water (10x25 ml) and the collected aqueous solution was evaporated 
to dryness in vacuo at 28°C to give trans-S-(1-propenyl)-L-cysteine (6) (130 mg, 70 %) as a 
white solid. 
 
1H NMR (300 MHz, D2O ): δ = 1.64 (br s, 3 H, CH3CH), 2.96 (dd, J = 14.9, 7.9 Hz, 1 H, 
SCHa), 3.15 (dd, J = 14.9, 3.0 Hz, 1 H, SCHb), 3.82 (m, 1 H, 
CHN), 5.83–5.91 (m, 2 H, CH=CH) 
Trans-S-(RS/SS)-diastereomers of S-(1-propenyl)-L-cysteine sulfoxide (2) 
[Namyslo 2006] 
S
NH2
OH
O
O
C6H11NO3S
177.22
 
3 % of aqueous hydrogen peroxide (0.98 ml, 0.86 mmol) was reacted with trans-S-
(1-propenyl)-L-cysteine (6) (132 mg, 0.82 mmol) overnight. Afterwards, the solvent was 
removed in vacuo at 28°C and the trans-S-(RS/SS)-diastereomers of S-(1-propenyl)-L-
cysteine sulfoxide (2) were obtained in quantitative yield as white solid. 
 
1H NMR (300 MHz, D2O ): δ (diastereomeric sulfoxide I) = 1.86 (d, J = 7.1 Hz, 3 H, 
CH3CH), 3.17 (dd, J = 13.7, 8.2 Hz, 1 H, SCHa), 3.56 (dd, 
J = 13.7, 5.6 Hz, 1 H, SCHb), 4.03 (dd, J = 8.2, 5.6 Hz, 1 H, 
CHN), 6.42 (d, J = 14.3 Hz, 1 H, CH=CHS), 6.63 (dq, 1 H, J =  
14.3, 7.1 Hz, CH3CH)  
δ (diastereomeric sulfoxide II) = 1.87 (d, 3 H, J = 7.1 Hz, 
CH3CH), 3.34 (m, 2 H, SCH2), 4.09 (dd, J = 8.0, 4.0 Hz, 1 H, 
CHN), 6.42 (d, J = 14.3 Hz, 1 H, CH=CHS), 6.58 (dq, 
J = 14.3, 7.1 Hz, 1 H, CH3CH) 
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Boc-L-glutamyl-α-t-butyl-N-oxo-succinimide ester (10) [Lawson 1991] 
O
O
OtBu
O
NH
N
O
O Boc
C18H28N2O8
400.42
 
1,3-Dicyclohexylcarbodiimide (240 mg, 1.163 mmol) was added to a solution of 
Boc-L-glutamic acid-α-t-butyl ester (350 mg, 1.155 mmol) and N-hydroxy-succinimide 
(135 mg, 1.173 mmol) in 3 ml of tetrahydrofuran at -20°C. The mixture was allowed to warm 
to room temperature and stirring was continued for 12 h. 0.1 ml of glacial acetic acid was 
added and the mixture was stirred for another 1 h. The reaction mixture was diluted with 
15 ml of ethyl acetate and filtered. The filtrate was washed with an ice-cold solution of 5 % 
sodium hydrogencarbonate in water (20 ml), water (10 ml) and brine (10 ml). Then it was 
dried using potassium sulphate and evaporated to give the Boc-L-glutamyl-α-t-butyl-N-oxo-
succinimide ester (10) (380 mg, 83 %). 
 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.45 (s, 9H, But), 1.48 (s, 9H, But), 1.96-2.08 (m, 
2H, βCH2 Glu), 2.19-2.37 (m, 2H, βCH2 Glu), 2.47-2.78 (m, 3H, 
αCH3Glu), 2.83 (s, 4H, CH2NSu), 5.15 (d, J = 7.2 Hz, 1H, NH) 
13C-NMR (75 MHz, CDCl3): δ [ppm] = 24.6 (CH2NSu), 27.2 (βCH2 Glu), 27.8 (But), 28.1 
(But), 52.9 (CHNH), 79.9 (CBut), 82.4 (CBut), 155.2 (C=O), 
167.8 (C=O), 169.8 (2 C=O), 170.6 (C=O) 
MS: [M+1]+ m/z 401.4 
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7.3 Results and discussion 
7.3.1 Isolation of GPCS from Allium cepa L. 
200 g of lyophilised onion powder was extracted with ethanol (15 %; v/v) and yielded in 150 g 
(75 %; w/w) of onion extract. A total of 10 cationic exchange column chromatographies were 
performed, each with 12 g of ethanolic extract. In sum, 9.13 g of GPCS-containing fractions 
were obtained corresponding to 4.6 % (w/w) of lyophilised onion powder. These fractions 
were used to perform anionic exchange column chromatographies which yielded in 1.58 g of 
GPCS-containing fractions (0.8 %; w/w). Finally, MPLC of 913 mg of these fractions yielded 
313 mg of pure GPCS (0.2 %; w/w). This amount is lower than that obtained by Wetli et al. 
[Wetli 2005] (0.7 %; w/w) which might be attributed to different contents of GPCS in the 
starting material. An overview over the extraction is given in Figure 11. 
Figure 11: Overview of the isolation of GPCS from onion 
Lyophilised onion powder, 100 % 
 
Ethanol 15 % 
 
Ethanolic extract, yield: 75 % 
 
Cationic exchange column chromatography 
 
Cationic GPCS-containing fractions, yield: 4.6 % 
 
Anionic exchange column chromatography 
 
Anionic GPCS-containing fractions, yield: 0.8 % 
 
MPLC 
 
GPCS, yield: 0.2 % 
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7.3.2 Synthesis of GPCS 
The synthesis of GPCS (1) consisted of three main parts:  
1. Synthesis of trans-S-1-propenyl-L-cysteine sulfoxide,  
2. Synthesis of N-protected and carboxyl-activated L-glutamic acid and  
3. Coupling of these two molecules.  
Synthesis of trans-S-1-propenyl-L-cysteine sulfoxide (2) [Namyslo 2006] 
To synthesise trans-S-1-propenyl-L-cysteine sulfoxide (2) two different pathways were 
performed.  
Pathway I 
Attempts to obtain trans-S-1-propenyl-L-cysteine sulfoxide (2) by the first procedure led to a 
mixture of the trans- and cis-isomers of S-1-propenyl-L-cysteine sulfoxide (2) (Figure 12). 
Figure 12: Synthesis of trans, cis-S-1-propenyl-L-cysteine sulfoxide 
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L-Cysteine hydrochloride (3) was alkenylated with allyl bromide [Lawson 1991]. It was 
performed in the presence of sodium in ethanol and yielded 78 % of S-(2-propenyl)-L-
cysteine. In the next two steps, S-allyl-L-cysteine (5) was isomerised and oxidised to 
trans, cis-S-(1-propenyl)-L-cysteine sulfoxide (2). Two different options were pursued. 
S-Allyl-L-cysteine (5) was oxidised with hydrogen peroxide and yielded the sulfoxide as a 
mixture of diastereomers [Yu 1994]. Attempts to isomerise this product with potassium tert-
butoxide in dimethyl sulfoxide according to Carson et al. [Carson 1966] failed. This might be 
explained by the configurations of S-(2-propenyl)-L-cysteine (11) possibly resulting in a 
6-membered transition state (12). 
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Because this option was not successful, the order of isomerisation and oxidation was 
changed. Treatment of S-allyl-L-cysteine (5) with potassium tert-butoxide in dimethyl 
sulfoxide resulted in a mixture of trans, cis-S-(1-propenyl)-L-cysteine (6) [Carson 1966] with 
the cis- isomer as the major product (60 % yield). To improve the yield of the trans product 
longer reaction times (7 days) are necessary. Oxidation of trans, cis-S-(1-propenyl)-L-
cysteine (6) was performed with an aqueous solution of 3 % aqueous hydrogen peroxide 
leading to trans, cis-diastereoisomers of S-(1-propenyl)-L-cysteine sulfoxide (2) (90 % yield, 
modification of the method described in [Yu 1994]). 
Pathway II 
Because the first pathway resulted in a mixture of trans- and cis-S-(1-propenyl)-L-cysteine 
sulfoxide (2), a second pathway was performed to obtain exclusively the trans product 
(Figure 13).  
Figure 13: Synthesis of trans-S-1-propenyl-L-cysteine sulfoxide 
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First, commercially available L-cysteine ethyl ester hydrochloride (4) was Boc-protected 
using di-tert-butyl dicarbonate and triethylamine in tetrahydrofuran, yielding N-Boc-L-cysteine 
ethyl ester (7) (98 %). Coupling with trans-1-bromoprop-1-ene in tetrahydrofuran under the 
catalysis of palladium(0) and purification by flash column chromatography, led to the 
trans-(prop-1-enyl) derivative (8) in 80 % yield from N-Boc-L-cysteine ethyl ester (7). The 
ethyl ester (8) was hydrolysed with lithium hydroxide giving the lithium carboxylate of 8. To 
obtain the propanoic acid (9), a cationic exchange resin was used, yielding 94 % of the 
product. The N-Boc deprotection was performed with trifluoroacetic acid in dichloromethane 
and yielded the unprotected amino acid derivative (6) (78 %). A quantitative oxidation of 
trans-S-(1-propenyl)-L-cysteine (6) was achieved by using an aqueous solution of 3 % 
hydrogen peroxide. 
Synthesis of N-protected and γ-carboxyl-activated L-glutamic acid 
Boc-L-glutamyl-α-t-butyl-N-oxo-succinimide ester (10) was generated from N-hydroxy-
succinimide (13), Boc-L-glutamic acid-α-t-butyl ester (14) and dicyclohexylcarbodiimide 
(DCC) in tetrahydrofuran and, yielding 83 % of the product [Lawson 1991] (Figure 14). 
Part II: Isolation of GPCS from Allium cepa L. and synthesis of GPCS 42 
 
Figure 14: Synthesis of Boc-L-glutamyl-α-t-butyl-N-oxo-succinimide ester 
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Coupling of trans-S-(1-propenyl)-L-cysteine sulfoxide (2) and N-protected 
and carboxyl-activated L-glutamic acid 
In order to obtain GPCS (1) the strategy was to couple trans-S-(1-propenyl)-L-cysteine 
sulfoxide (2) with N-protected and carboxyl-activated L-glutamic acid (10). This compound is 
known to react predominantly at the γ-function.  
The Boc-group was selected for N-protection because it can easily be removed by 
trifluoroacetic acid in dichloromethane. In order to check the feasibility of amide coupling and 
to find optimal conditions for this reaction, different bases, solvents and reaction times for the 
amide coupling were tested (Table 11). Unfortunately, the product could not be formed. 
Table 11: Working conditions for the coupling of Boc-L-glutamyl-α-t-butyl-N-oxo-succinimide ester and trans-S-
(1-propenyl)-L-cysteine sulfoxide (2) 
Base Solvent Time of reaction Product 
Triethylamine Acetone 1 – 7 days No reaction 
Sodium hydrogencarbonate Acetonitrile 1 – 7 days No reaction 
Triethylamine Dimethylformamide 1 day No reaction 
 
Figure 15: Amide coupling of trans-S-(1-propenyl)-L-cysteine sulfoxide (2) with N-protected and carboxyl-
activated L-glutamic acid (10) 
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It is supposed that the coupling reaction with activated glutamic acid under standard 
conditions results in decomposition of S-(1-propenyl)-L-cysteine sulfoxide (2). The fact that 
the evaporation of 2 has to be performed at very mild conditions, at 28°C, and decomposition 
was observed when the temperature was increased, indicates instability of the substance. A 
second possibility is the internal elimination of sulfoxides to form olefins and sulfenic acids 
which may inhibit the coupling process (Figure 16) [Cubbage 2001]. 
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Figure 16: Internal elimination of sulfoxides 
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Therefore, coupling at an earlier stage of the synthesis might lead to the desired product 
(Figure 17). 
Figure 17: Alternative coupling strategy I 
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Furthermore, more efficient carboxyl activation groups for the coupling with the alpha amino 
acid could be tested. One possibility to couple the two amino acids might be the reaction of 6 
with the N-protected L-glutamic anhydride (18), which is known to react predominantly at the 
gamma carbonyl function (Figure 18). This protocol has been used by Van den Broek et al.  
in the total synthesis of gamma-glutamylmarasmine [Van den Broek 1987]. 
Figure 18: Alternative coupling strategy II 
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In addition, different protecting groups have to be taken into account. For N-protection the 
phthaloyl group, which can be removed by hydrazinolysis, as well as the Fmoc 
(9-Fluorenylmethyloxycarbonyl) could be investigated. 
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8 Part III: Pharmacodynamic and pharmacokinetic 
properties of GPCS in vitro and in vivo 
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8.1 Materials and methods 
8.1.1 Effects of GPCS on the activity, activation and recruitment of 
osteoclasts in vitro 
This section contains the description of materials and methods used to determine the effect 
of GPCS on the activity, activation and development of OCs. 
Materials 
Medium 199, N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) solution (HEPES), 
Triton X-100, Hoechst H33342, calcitonin, paraformaldehyde (PFA), concentrated 
hydrochloric acid, L-cysteine, 1 M tartrate solution, 2.5 M acetate solution pH 5.2, napthol 
AS-BI phosphoric acid 12.5 mg/ml in N,N-dimethyl formamide, bovine serum albumin (BSA) 
and Fast Garnet GBC Salt were purchased at Sigma-Aldrich and Merck. Minimum essential 
medium with Earle’s salts and without phenol red (MEM), alpha-minimum essential medium 
with Earle’s salts (α-MEM), minimum essential medium with Hanks’s salts (MEM Hank’s), 
penicillin-streptomycin-solution (P/S; containing 10’000 units/ml penicillin G sodium and 
10’000 µg/ml streptomycin sulphate in 0.85 % saline), fetal bovine serum (FBS), and 
glutamine were obtained from Gibco. Alexa Fluor 488 phalloidine was purchased from 
Molecular Probes, RANKL from Peprotech, IMMU-MOUNT from Thermo Shandon, and M-
CSF was a gift from Chiron Corporation. Phosphate buffered saline (PBS) was prepared with 
8.0 g/l of sodium chloride, 1.44 g/l of disodium hydrogen phosphate dihydrate, 0.2 g/l of 
potassium chloride and 0.2 g/l of potassium dihydrogen phosphate in bidistilled water. These 
chemicals were obtained from Sigma-Aldrich or Merck. γ-Glutamyl-L-cysteine-ethylester, 
glycyl-L-cysteine, glutamyl-glycine and glycyl-L-valine were purchased from Bachem. S-Allyl-
L-cysteine was synthesised according to the procedure described in chapter 7 Part II: 
Isolation of GPCS from Allium cepa L. and synthesis of GPCS. Bidistilled water was 
prepared in house. 
Glass coverslips were purchased from Marienfeld GmbH & Co. KG. Dentin slices were in 
house custom made from ivory goods confiscated by customs. Sputter coating of dentin 
slices with gold was performed on a sputter machine SCD 004 from BALZERS UNION 
Limited. 
All cell culture media were supplemented with 1 % P/S. 
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Study of osteoclast activity I: actin ring assay 
Isolation of osteoclasts from neonatal rat bones 
OCs were isolated from femora and tibiae of 2-day-old Wistar Hanlbm rats (bred in house at 
the Central Animal Facility of the Medical Faculty). The bones were cut into small pieces in 
Medium 199 containing 20 mM HEPES (pH 7.3). After repeated (three times) washing, the 
supernatants were pooled and centrifuged. The cell pellet was resuspended in Medium 199 
containing 10 % heat-inactivated FBS (FBS Hia). 50 µl aliquots of the cell suspension were 
placed on ø 13 mm glass coverslips. Before use, these coverslips were coated overnight with 
a 0.9 % solution of sodium chloride containing 30 % FBS Hia, washed with water and dried. 
OCs isolated from femora and tibiae from eight rats were usually distributed onto 32 
coverslips. 
To allow adherence of OCs, the coverslips were incubated at 37°C for 1 h. Non-adherent 
cells were removed by washing two times with Medium 199 containing 10 % FBS Hia. 
Thereafter, the coverslips were transferred into 24-well-plates containing Medium 199 
supplemented with 10 % FBS Hia and were incubated at 37°C. After 3 h the medium was 
changed and the cells were again incubated for 15 min, if not stated otherwise. The medium 
was removed and Medium 199 containing 10 % FBS Hia, with or without test substances, 
was added. 
Staining of actin and nuclei 
After removal of the culture medium, the cells were fixed with 3 % PFA in PBS for 10 min and 
washed three times with PBS. The cells were permeabilised with 0.25 % Triton X-100 in PBS 
on ice for 5 min and then washed again two times with cooled PBS.  
Subsequently, the cells were stained for actin by putting the coverslips upside down on drops 
of 30 µl Alexa Fluor 488 phalloidine (5 Us/ml, dissolved in PBS with 1 % BSA) in a box with a 
humid atmosphere for 40 min. After carefully dipping the coverslips two times in PBS, the 
nuclei were stained with the same method with Hoechst H33342 (5 µg/ml, dissolved in PBS) 
for 5 min. The coverslips were subsequently gently washed twice with demineralised water 
and dried at room temperature before they were embedded on microscope slides with IMMU-
MOUNT. 
The slides were blinded and the number of multinucleated OCs (nuclei > 2) and the number 
of OCs containing actin ring(s) were counted on a Nikon Eclipse E800 microscope (actin, 
excitation: 465 – 495 nm, fluorescence: 515 – 555 nm, beam splitter reflecting 
light < 505 nm; nuclei, excitation: 340 – 380 nm, fluorescence: 455 – 485 nm, beam splitter 
reflecting light < 400 nm). The number of OCs containing one or more actin rings was 
expressed as percentage of the total number of OCs and is a measure of activation of OCs. 
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Study of osteoclast activity II: pit assay 
Isolation of osteoclasts from neonatal rat bones 
OCs were isolated from bones of 2-day-old rats by the following procedure.  
A) Femora were dissected in MEM. After removal of soft tissues, the bones were finely 
chopped in MEM supplemented with 10 % FBS and acidified with 10 mmol/l hydrochloric 
acid. The supernatant was transferred to a 15-ml flask. B) The remaining bone pieces were 
washed twice with acidified MEM containing 10 % FBS. The supernatant was collected and 
pooled with the supernatant collected in step A). C) This cell suspension was vortexed for 
20 sec and allowed to settle for 30 sec. The supernatant was transferred into a new 15-ml 
flask. D) 3 ml of acidified MEM containing 10 % FBS were added to the remaining bone 
pieces and the suspension was vortexed for 20 sec. After 30 sec the supernatant was 
combined with the supernatant collected in step C). 
800 µl of the cell suspension was placed on 8 dentin slices which were placed in one well. 
After incubation for 45 min in 5 % carbon dioxide (CO2)/95 % air at 37°C to allow cells to 
adhere, the dentin wafers were rinsed by dipping them carefully into sterile PBS. They were 
transferred into 48-well plates, which contained the pre-equilibrated test substances 
(dissolved in MEM with 10 % FBS) or MEM with 10 % FBS alone as control. The slices were 
incubated at 37°C in 5 % CO 2/95 % air for 24 h. 
Quantitation of osteoclasts and resorption 
To stop the resorption, the cells were fixed with 3 % PFA in PBS for 10 min and thereafter 
washed three times with demineralised water. To visualise the OCs, the cells were stained 
for tartrate resistant acid phosphatase (TRAP). For the preparation of the staining solution, 
41 ml of demineralised water, 5 ml of a 1 M tartrate solution, 2 ml of a 2.5 M acetate solution 
pH 5.2 and 2 ml of Napthol AS-BI phosphoric acid 12.5 mg/ml in N,N-dimethyl formamide 
were mixed for 1 min with 10 – 15 mg Fast Garnet GBC Salt. The solution was filtered and 
used to stain the cells for 7 min. Finally, the dentin wavers were washed three times with 
demineralised water and air dried. 
Multinucleated OCs (nuclei ≥ 2) were counted on a Nikon Optiphot microscope. 
The cells were removed from the dentin wavers by gentle brushing with a toothbrush in 70 % 
isopropanol and afterwards in demineralised water. The absence of cells and debris was 
assessed with a microscope. The dentin discs were sputter-coated with gold and the 
resorption pits were counted blind on a Nikon Optiphot microscope. 
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Assessment of osteoclast formation in vitro 
Culture of osteoclasts from bone marrow cells 
Bone marrow cells, containing the precursor cells of OCs, were isolated from 6-weeks old 
mice (male, ddy) after euthanasia with CO2. Femora were dissected, placed in MEM-Hank`s 
and soft tissue and muscles were removed. The articular ends were cut away and the bones 
were flushed with 5 ml MEM-Hank`s each. After centrifugation at 250 x g for 5 min the cell 
pellet was resuspended in 10 ml α-MEM containing 10 % FBS. Cells were counted in Turk-
solution, which stains the nuclei of leucocytes, in a Neubauer chamber. Thereafter, the cell 
suspension was diluted with α-MEM containing 10 % FBS to 60’000 cells per ml. 50 µl of the 
cell suspension was distributed into each well of 96-well plates containing 50 µl of α-MEM 
supplemented with 10 % FBS, 60 ng/ml CSF and 10 ng/ml RANKL, with or without the 
substances to be tested, for a final concentration of 30 ng/ml CSF and 5 ng/ml of RANKL and 
the required concentrations of test substances. Media containing test substances were 
adjusted to the same pH as the control medium with 1 M sodium hydroxide solution and 
filtered through a 0.2-µm filter before use. The cells were incubated in 5 % CO2/95 % air at 
37°C. After three days, the medium was changed and cells were further incubated. 
Depending on the stage of maturation of the cells in the control group, the cultures were 
usually fixed on day 4 or 5 of the experiment. 
Quantitation of osteoclast development 
Cells were fixed with 4 % PFA in PBS for 10 min and washed three times with demineralised 
water before staining the cells for TRAP. The staining solution was prepared as described 
above. Cells were stained for 5 min and washed three times with demineralised water. 
Multinucleated, TRAP+ cells were counted (nuclei ≥ 3) on a Wild-Leitz Diavert microscope. 
Statistical analysis 
The results were tested using analysis of variance (ANOVA, Bonferroni) using WinSTAT® 
version 2005.1 for Microsoft® Excel. 
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8.1.2 Studies to determine the stability of GPCS in simulated gastric 
acid and simulated intestinal fluid 
In this section, materials and methods of studies on the stability of GPCS in simulated gastric 
acid and simulated intestinal fluid are shown.  
Materials 
As GPCS was not commercially available it was isolated as described in chapter 7 Part II: 
Isolation of GPCS from Allium cepa L. and synthesis of GPCS. 
Acetonitrile Chromasolv®, methanol Chromasolv®, pepsin and pancreatin were purchased 
from Sigma-Aldrich and ortho phosporic acid 85 %, sodium chloride, concentrated 
hydrochloric acid, potassium dihydrogen phosphate and sodium hydroxide were obtained 
from Merck. Onions were purchased on the local food market in Bern and lyophilised, 
subsequently pulverised, and stored at -20°C until use. 
Bidistilled water was prepared in house. 
Instrumentation 
See section 6.1.1 Quantitation of GPCS using HPLC-DAD. 
Chromatographic conditions and method development 
Optimisation of mobile phase 
The mobile phase consisted of solvent A with bidistilled water containing 0.05 % phosphoric 
acid 85 % (v/v) and solvent B with acetonitrile containing 0.05 % phosphoric acid 85 % (v/v). 
To optimise the mobile phase, different water contents were tested isocratically: 25, 20, 15, 
10, 7.5 and 5 % of solvent A. The flow was 0.7 ml/min. 
Selection of stationary phase and column temperature 
Two different stationary phases were tested to find optimal conditions for the determination of 
GPCS in simulated gastric acid and simulated intestinal fluid:  
A) 125 x 4 mm I.D. column, packed with Spherisorb ODS-1, particle size 3.0 µm and a 
8 x 4 mm I.D. precolumn, packed with the same column material (Machery-Nagel), and  
B) 150 x 4.6 mm I.D. column, packed with Shodex ODP2 HP-4D, particle size 5 µm 
(Infochroma).  
The temperature of the columns was 40°C. 
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Detection 
Wavelength for the quantitation of GPCS was UV 195 ± 4 nm with online recording of the UV 
spectra from 190 - 400 nm (DAD). 
Peak identification (selectivity/specificity) 
Chromatographic selectivity: The retention time of the analyte was assigned with the 
corresponding standard. 
Spectroscopic selectivity: The DAD UV spectra in the range of 190 – 400 nm were compared 
to the spectra of the standards. The recorded spectra were also used for the peak purity 
check. Blank samples of simulated gastric acid and simulated intestinal fluid were analysed 
to exclude interferences of the analytes with the matrices. 
Calibration and linear range 
Different stationary phases were used in this study. Thus, two calibrations of GPCS were 
performed by applying the external standard and linear regression analysis over the 
concentration ranges of 10 µg/ml to 200 µg/ml (Spherisorb ODS-1) and 5 µg/ml to 125 µg/ml 
(Shodex ODP2), respectively, for GPCS. To obtain the calibration graph for GPCS the area 
of GPCS was plotted against the concentration of GPCS.  
Calibrator concentrations of 10, 50, 100, 150, 200 µg/ml GPCS (Spherisorb ODS-1) and 5, 
50, 125 µg/ml GPCS (Shodex ODP2) were prepared in water/acetonitrile (1/3; v/v) from a 
stock solution of GPCS. Each sample was measured three times. 
Stability of GPCS in simulated gastric acid 
4.9 mg of GPCS were added to 5.0 ml of simulated gastric acid (preparation see below) and 
kept under stirring at 37°C. After 0.25 h, 50 µl of the reaction mixture was taken, diluted to 
500 µl with water/acetonitrile (1/3; v/v) and analysed immediately using HPLC-DAD. The 
same procedure was repeated after 0.5, 1, 2, 4, 6 and 24 h of reaction. 
Preparation of simulated gastric acid [Europäische Pharmakopöe 2005]: 200.0 mg of sodium 
chloride and 320.7 mg pepsin were dissolved in bidistilled water. After adding 8 ml of 1 N 
hydrochloric acid, the solution was diluted to 100.0 ml with bidistilled water. 
Stability of GPCS in simulated intestinal fluid 
2.3 mg of GPCS were added to 2.3 ml of simulated intestinal fluid (preparation see below) 
and kept under stirring at 37°C. After 0.25 h, 50 µl of reaction mixture was taken, diluted to 
500 µl with water/acetonitrile (1/3; v/v) and analysed immediately using HPLC-DAD. The 
same procedure was repeated after 0.5, 1, 2, 4, 6 and 24 h. 
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Preparation of simulated intestinal fluid (SIF) [The United States Pharmacopoeia 2006]: 
0.68 g of potassium dihydrogen phosphate was dissolved in 25 ml of bidistilled water. 7.7 ml 
of a 0.2 N solution of sodium hydroxide, 50 ml of bidistilled water and 1.0 g of pancreatin 
were added and mixed. The resulting suspension was adjusted to pH 6.8 by the addition of a 
0.2 N solution of sodium hydroxide. It was diluted to 100.0 ml with bidistilled water and 
filtrated. 
Stability of GPCS in water 
2.0 mg GPCS were added to 2.0 ml bidistilled water and kept under stirring at 37°C. After 
0.25 h, 50 µl of the reaction mixture was taken, diluted to 500 µl with water/acetonitrile (1/3; 
v/v) and analysed immediately using HPLC-DAD. The same procedure was repeated after 
0.75, 1.25, 2, 4, 6 and 24 h. 
Determination of GPCS in Allium cepa L. powder incubated in simulated 
intestinal fluid 
500.5 mg lyophilised powder of Allium cepa L. were added to 10.0 ml of simulated intestinal 
fluid and kept under stirring at 37°C. After 0, 0.2 5, 0.75, 1.25, 2, 4, 6 and 24 h, 500 µl of the 
reaction mixture was taken and filtrated. 50 µl of the filtrate was diluted with 450 µl of 
acetonitrile/water (9/1; v/v) containing 0.05 % phosphoric acid 85 %, filtrated again, and 
analysed immediately using HPLC-DAD. 
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8.1.3 Pilot studies to determine the pharmacokinetic properties of 
GPCS in rats 
The following experiments were performed to assess the pharmacokinetic properties of 
GPCS in vivo. 
Animals 
The pharmacokinetic properties of GPCS were studied in male Wistar Hanlbm rats. Rats 
were 8 – 10 weeks old and weighed about 250 g. They were kept in house in the Central 
Animal Facility of the Medical Faculty in compliance with the Swiss and US National Institute 
of Health guidelines for care and use of experimental animals. The State Committee for the 
Control of Animal Experimentation approved the performed experiments (authorisation 
number 48/05).  
Experimental protocol 
After a fasting period of 20 h, rats received 250 µl of a 10 mg/ml solution of GPCS (dissolved 
in 0.9 % sodium chloride) either by gavage or injection into the tail vein. Blood samples of 
maximum 150 µl were collected by stab puncture of the lateral tail vein into heparin coated 
Eppendorf tubes 5, 15, 30, 60 and 180 min after GPCS administration. A basal blood sample 
was taken one day before. After collection, blood was centrifuged immediately at 800 x g, at 
4°C for 10 min, and the plasma was stored at -70°C until analysis. Samples were analysed 
using HPLC-DAD and HPLC-MS/MS after preparation with SPE.  
Pharmacokinetic parameters were estimated using the area ratio of GPCS/I.S. versus time. 
Areas under the curve (AUC), the time points of the maximum area ratio GPCS/I.S. (tmax) and 
the oral bioavailabilities were calculated using PK functions (Add-In for Microsoft Excel). 
Standards, solvents and chemicals 
As GPCS was not commercially available it was isolated as described in chapter 7 Part II: 
Isolation of GPCS from Allium cepa L. and synthesis of GPCS. 
Bidistilled water was prepared in house. Acetonitrile Chromasolv®, methanol Chromasolv®, 
ortho phthaldialdehyde, ortho phosporic acid 85 %, concentrated hydrochloric acid, 
ammonium hydoxide solution 25 %, tert-butylmercaptan, sodium dihydrogen phosphate 
hydrate, disodium hydrogen phosphate dihydrate, sodium hydroxide, L-aspartyl-L-
phenylalanine and sodium tetraborate decahydrate were purchased at Sigma-Aldrich and 
Merck. 0.45-µm filters were obtained from Infochroma. 
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To prepare the borate buffer pH 9.5, 4.77 mg of sodium tetraborate decahydrate was 
dissolved in 200 ml of water. The pH was adjusted to 9.5 with a solution of 10 M sodium 
hydroxide, and water was added to obtain a final volume of 250.0 ml.  
The derivatisation reagent was prepared by dissolution of 140 mg of ortho phthaldialdehyde 
in 5 ml of methanol and addition of 200 µl of tert-butylmercaptan. The volume was adjusted 
with borate buffer pH 9.5 to 50.0 ml.  
1.93 g sodium dihydrogen phosphate hydrate and 2.53 g disodium hydrogen phosphate 
dehydrate were dissolved in 1000.0 ml of water to obtain the phosphate buffer solution. The 
pH was adjusted with concentrated hydrochlorid acid to 6.5. 
Instrumentation 
HPLC-DAD 
See section 6.1.1 Quantitation of GPCS using HPLC-DAD. 
HPLC-MS/MS 
The HPLC system consisted of an Agilent 1100 Series degasser, binary pump, thermostated 
column compartment (Agilent Technologies), MPS 3C autosampler with wash station 
(Gerstel AG). The HPLC system was coupled to an API 5000 triple quadrupole mass 
spectrometer with an electrospray Turbo V ionisation source (Applied Biosystems, MDS 
Sciex). All data were acquired and processed using Analyst 1.4.2 software. 
Method development 
SPE parameters 
Four SPE columns with different column materials, Oasis MAX 3 cc SPE column, Oasis MAX 
1 cc SPE column, Oasis MCX 1 cc SPE column and Oasis WAX 1 cc SPE column (Waters) 
were tested using various extracting solvents.  
Prior to SPE, samples were prepared as follows. For the acidic and basic diluents, 20 µl of 
concentrated phosphoric acid (for Oasis MCX and Oasis WAX) and 20 µl of concentrated 
ammonium hydroxide (for Oasis MAX), respectively, were added to 500 µl of water. 500 µl of 
0.11 mg/ml GPCS in water was diluted with 500 µl of the acidic or basic diluent. SPE was 
performed as described in Table 12 using a manual Adsorbex sample preparation unit 
(Merck).  
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Table 12: SPE method development for the determination of GPCS in plasma 
SPE Column Oasis MAX 3 cc Oasis MAX 1 cc Oasis MCX 1 cc Oasis WAX 1 cc 
Conditioning 2 ml Methanol 1 ml Methanol 1 ml Methanol 1 ml Methanol 
 2 ml Water 1 ml Water 1 ml Water 1 ml Water 
Loading 
Diluted basic 
sample 
Diluted basic 
sample 
Diluted acidic 
sample 
Diluted acidic 
sample 
Washing 
2 ml 5 % 
Ammonium 
hydroxide solution 
1 ml 5 % 
Ammonium 
hydroxide solution 
1 ml 2 % Formic 
acid in water 
1 ml 5 % 
Ammonium 
hydroxide solution 
 2 ml Methanol 1 ml Methanol 1 ml Methanol 1 ml Methanol 
Elution 
2 ml 2 % Formic 
acid in 
methanol/water 1/1 
(v/v) 
1 ml 2 % Formic 
acid in 
methanol/water 1/1 
(v/v) 
1 ml 2 % 
Ammonium 
hydroxide in 
methanol 
1 ml 2 % 
Ammonium 
hydroxide in 
methanol 
 
The eluates were evaporated to dryness under a stream of nitrogen at 40°C. 500 µl of 
acetonitrile/water (3/1; v/v) were added to the residue. The test tube containing the solution 
was closed, vortexed three times and sonicated for 3 min. The solution was filtered using a 
0.45-µm filter and injected into the HPLC-DAD. To determine the most efficient extraction 
conditions, a solution of 0.11 mg/ml of GPCS in water was directly analysed using HPLC-
DAD and the amount of GPCS found was directly related to the recoveries of GPCS in the 
different eluates. 
Extraction procedure of plasma samples 
The preparation of the plasma solution prior to the SPE was performed as follows. 100 µl of a 
1.67 % solution of ammonium hydroxide was mixed with 50 µl plasma. 50 µl of internal 
standard (28 µl/ml of L-aspartyl-L-phenylalanine in water) and 800 µl of water were added, 
and the solution was vortexed three times. Plasma samples were purified with Oasis MAX 
3 cc SPE columns (Waters) using an ASPEC robotic system (Automated Sample 
Preparation with Extraction Columns; Gilson; see Figure 8) or a manual Adsorbex sample 
preparation unit (Merck). The elution scheme is described in Table 13.  
Table 13: Elution scheme: SPE of plasma for the determination of GPCS 
Conditioning Methanol 2 ml 
 Water 2 ml 
Loading Sample prepared as described above 0.9 ml 
Washing 5 % Ammonium hydroxide solution 2 ml 
 Methanol 2 ml 
Elution 2 % Formic acid in methanol/water 1/1 (v/v) 2 ml 
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The eluate was evaporated to dryness under a stream of nitrogen at 40°C. 100 µl of 
cetonitrile/water (3/1; v/v) were added to the residue. The test tube containing the solution 
was closed, vortexed three times and sonicated for 3 min. The solution was filtered using a 
0.45-µm filter and analysed without further treatment, if not stated otherwise. 
Chromatographic conditions and method development 
System A: HPLC-DAD 
Stationary phase and column temperature 
As stationary phase a 125 x 4 mm i.d. column, packed with Spherisorb ODS-1, particle size 
3.0 µm and a 8 x 4 mm i.d. precolumn, packed with the same material (Machery-Nagel) was 
used. The column temperature was 40°C. 
Determination of GPCS without derivatisation 
10 µl of the sample were injected into the HPLC.  
Mobile phase 
The mobile phase consisted of solvent A with water containing 0.05 % phosphoric acid (v/v) 
and solvent B with acetonitrile containing 0.05 % phosphoric acid (v/v). Separation was 
performed isocratically using 80 % solvent B for 30 min.  
Detection 
The wavelength for the quantitation of GPCS was 195 ± 4 nm with online recording of the UV 
spectra from 190 to 400 nm (DAD). 
Determination of GPCS with derivatisation 
Derivatisation of samples was performed by adding 200 µl of derivatisation reagent 
(preparation see above) to 50 µl of the sample. 10 µl was injected into the HPLC. 
Optimisation of mobile phase 
The mobile phase consisted of solvent A with phosphate buffer and solvent B with 
acetonitrile. To obtain optimal conditions of the mobile phase, different contents of phosphate 
buffer were tested isocratically: 5, 25, 50, 75 and 95 % of solvent A. The flow was 1.0 ml/min. 
Detection 
The wavelength for the quantitation of the GPCS derivative was 335 ± 4 nm with online 
recording of the UV spectra from 190 to 400 nm (DAD). 
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System B: HPLC-MS/MS 
Samples were diluted 1:100 with water and 10 µl  injected into the HPLC. 
Mobile Phase 
The mobile phase consisted of solvent A with acetonitrile containing 0.05 % formic acid (v/v) 
and solvent B with water containing 0.05 % formic acid (v/v). Separation was performed 
isocratically using 5 % of solvent A for 5 min. The column was washed with 95 % solvent B 
for 2 min and then reequilibrated to the initial conditions for 5 min. The flow was 0.2 ml/min.  
Stationary phase and column temperature 
A 150 x 2.1 mm i.d. column, packed with Synergi Fusion RP 80, particle size 4.0 µm 
(Phenomenex) was used. The column temperature was 23°C. 
Optimisation of detection 
Acquisition was performed in the Multi reaction monitoring mode (MRM) and the protonated 
(ESI+) adduct ion was chosen as the precursor. Source conditions were established as 
follows: ion spray voltage 5 kV (ESI+); collision gas, 5 psi; curtain gas, 30 psi; ion source gas 
1 (nebuliser gas) 65 psi and 2 (turbo gas), 80 psi; ion source temperature, 500°C. High purity 
nitrogen (> 98 %) was used as desolvation, nebulisation and collision gas. MS/MS parameter 
optimisation was obtained by direct infusion at 10 µl/min of 50 ng/ml individual standard 
solutions in 50 % aqueous methanol. Declustering potential (DP), collision energy (CE) and 
cell exit potential (CXP) voltages were established for each analyte. The dwell time was set 
to 200 msec. 
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8.1.4 Experimental design to assess bone resorption in vivo 
A previously developed and validated in vivo rat model to monitor acute changes in bone 
resorption [Antic 1996, Egger 1994, Muhlbauer 1990, Muhlbauer 1995, Muhlbauer 1999] was 
used to evaluate the effects of onion containing GPCS, onion without GPCS, allyl-cysteine, 
and γ-glutamyl-cysteine-ethylester on bone resorption. The following experiments were 
performed. 
Animals 
For each experiment, three female Wistar Hanlbm rats, with twelve 2 – 3 days old male pups 
each, were purchased from Charles River Wiga GmbH. The animals were kept in house in 
the Central Animal Facility of the Medical Faculty in compliance with the Swiss and US 
National Institute of Health guidelines for care and use of experimental animals. The State 
Committee for the Control of Animal Experimentation approved the performed experiments 
(authorisation number 48/05).  
Experimental protocol 
The skeleton of growing male rat pups was labelled by injecting [7-3H(N)]-tetracycline for 6 
weeks. After one week of recovery, the rats were weighed and transferred to metabolic 
cages where they were acclimatised for 10 days. During the following 10 days radioactivity 
was measured in the 24 h urine to determine base line excretion. Afterwards, the animals 
were weighed again and 24 animals were selected for the treatment phase. The animals 
were assigned to one of four groups (n = 6). The diet was changed to a semi-purified diet 
supplemented with different doses of onion, allyl-cysteine or γ-glutamyl-cysteine-ethylester. 
Semi-purified diet without supplements was used as the control. Under treatment, the 
measurement of the urinary secretion of [3H] was continued for 10 days. At the end of the 
experiment the rats were euthanised with carbon dioxide. If not stated otherwise, the 
vertebrae were excised for microCT analysis (Micro-CT 40, Scanco Medical AG) and, as 
structural indices, the bone volume/total volume quotient (BV/TV) and the connection density 
were determined. A schematic overview of the experimental protocol is given in Figure 19. 
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Figure 19: Time course of experiments to determine bone resorption in rats 
Injection of [7-3H(N)]-tetracycline into rats 
From the first week on, male rat pups were injected subcutaneously with increasing doses of 
a [7-3H(N)]-tetracycline solution (10 µCi/ml [7-3H(N)]-tetracycline / 0.9 % sodium chloride 
solution) according to the scheme shown in Table 14.  
Table 14: Scheme for injecting [7-3H(N)]-tetracycline 
solution into rats 
Age of rats 
[week] 
Injection volume 
[µl] 
1 1 x 100 
2 2 x 100 
3 2 x 150 
4 2 x 200 
5 2 x 250 
6 2 x 250 
Preparation of diet 
Standard diet was prepared by adding demineralised water to SODI 2134 diet powder (Kliba-
Mühlen) in a ratio of 5/4 (powder/water, w/w) and by adding calcium gluconate, sodium 
dihydrogen phosphate and disodium hydrogen phosphate (Merck) to obtain a final 
concentration of 1.1 % calcium and 1.2 % phosphorus. To prevent interferences of natural 
components of a standard diet with bone resorption, rats received a semi-purified diet during 
the treatment phase [Brown 2001] which contained an animal protein source instead of a 
plant protein source. Semi-purified diet was prepared by adding demineralised water to SODI 
2160 diet powder (Kliba-Mühlen) in a ratio of 6/5 (powder/water, w/w) to get a pastry 
consistence. Detailed compositions of the diets are given in section 11.3 Appendix 3: 
Composition of SODI 2134 and SODI 2160 diet powders. 
Diets supplemented with onion were prepared by adding the appropriate amount of 
lyophilised onion powder to the semi-purified diet followed by thorough mixing. Usually, the 
diet for one experiment was prepared and stored in aliquots at -20°C until use.  
Labelling
[3H]Tetracycline
2 x per week
6 weeks 1 week 10 d10 d
Recovery
10 d
Acclimatisation Baseline Treatment
Transfer to 
metabolic
cages
Birth
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To prepare diets containing allyl-cysteine (synthesised as described in chapter 7 Part II: 
Isolation of GPCS from Allium cepa L. and synthesis of GPCS) or γ-glutamyl-cysteine-
ethylester (Bachem), solutions of these substances in demineralised water were added to 
30-g portions of the semi-purified diet and thoroughly mixed. Diets were fed to the rats 
immediately after preparation. 
Feeding of animals 
During the labelling and recovery phase, animals were kept in conventional cages and were 
allowed free access to food pellets (Kliba 3436, Kliba) and water. After transfer to the 
metabolic cages, during the acclimatisation and base line periods, the rats received 
demineralised water ad libitum and 30 g of standard diet every day at 11 am, if not stated 
otherwise. During the treatment phase rats obtained demineralised water ad libitum and 30 g 
of semi-purified diet (including the test compounds) every day at 11 am. Except for the Kliba 
3436 diet, all diets were provided in stainless steel cups. 
Determination of [3H] excretion in urine 
24-h urine samples were collected every day at 11 am. The volume of each urine sample 
was determined and aliquots of 1 ml, acidified with 0.1 M of hydrochloric acid, were mixed 
with 10 ml of Irga-Safe Plus scintillator (Perkin Elmer). Quantitation of the [3H] content was 
performed by liquid scintillation counting using a TriCarb Liquid Scintillation Analyzer 2200CA 
(Packard), and the result was calculated for the volume of the collected urine. 
Assignment of rats into groups 
After 10 days of baseline measurement of the urinary [3H] excretion, the rats were divided 
into 4 groups (n = 6) as follows:  
In the first experiment the rats with high fluctuation and with very high or very low 
[3H] excretions were excluded from the experiment. The 24 remaining rats were randomly 
assigned into the 4 groups by a computerised randomisation programme using the Web site 
Randomization.com <http://www.randomization.com>. 
In the second and third experiment, during the 10 days of baseline measurement the 
following calculations were performed. The daily means of the [3H] excretion from all rats 
( X ) and the absolute deviation of the individual rat’s daily value from this mean (l iXX − l) 
were calculated. After the 10 days, for each rat the sum of their daily [3H] excretion values 
(∑ iX ), the sum of their deviation from the daily means (∑ iXX − ), and the sum of their 
absolute deviation value from the daily mean (∑l iXX − l) were calculated. 
These values were used to create a ranking, on top the rat with the least, and on the bottom 
the rat with the highest absolute deviation sum (∑l iXX − l). The 12 rats with the highest 
Part III: Pharmacodynamic and pharmacokinetic properties of GPCS in vitro and in vivo 61 
 
values were excluded from the experiment. The 24 remaining rats were divided into groups 
as follows. The first 12 rats from the ranking were set beforehand in the groups (3 rats per 
group). It was important that rats with negative and rats with positive deviation sums 
(∑ iXX − ) were homogeneously distributed within the groups. To assign the 12 remaining 
rats, a computer programme was written [Mabboux 2007] enabling groups of 6 animals with 
equal means of their cumulative [3H] excretions (∑ iX ). 
Statistical analysis 
The results were evaluated using analysis of variance (ANOVA, Bonferroni) using 
WinSTAT® version 2005.1 for Microsoft® Excel. 
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8.2 Results 
8.2.1 Effects of GPCS on the activity, activation and recruitment of 
osteoclasts in vitro 
In this section the results of experiments which were performed to assess the effect of GPCS 
on OC activity and on OC recruitment in vitro are presented. In addition, the influence on OC 
development of substances, which are structurally related to GPCS, is shown. 
Effects of GPCS on osteoclasts with actin ring(s) 
GPCS was shown to inhibit the resorption activity of OCs in vitro [Wetli 2005]. To investigate 
effects on the activation of OCs, the cells were treated with GPCS and the number of OCs 
containing actin rings was determined. 
To follow the development of actin rings in OCs over time and to establish optimal 
experimental conditions, the total number of OCs and the number of OCs with actin rings 
after incubation with Medium 199 containing 10 % FBS was determined over 21 h. The 
percentage of OCs with actin ring(s) increased up to 60 %, reaching a maximum within 3 h of 
incubation thereafter dropped to zero within the following 18 h. The number of OCs 
decreased after 5 h of incubation (Figure 20). 
Figure 20: Time course to follow the development of actin rings in OCs after adherence on glass coverslips. OCs 
were incubated with medium for up to 21 h. The data represent the mean ± s.d. (n = 6) of one experiment. 
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In order to investigate the effect of GPCS on activated OCs, OCs were pre-incubated in 
medium for 3 h. A further increase of OCs with actin rings was induced if medium was 
Part III: Pharmacodynamic and pharmacokinetic properties of GPCS in vitro and in vivo 63 
 
changed after these 3 h of preincubation and cells were incubated for another 15 min (data 
not shown). OCs were subsequently treated with Medium 199 containing 10 % FBS Hia and 
0, 2 and 8 mM of GPCS. Calcitonin, a potent inhibitor of OC activity, was used as a positive 
control at a concentration of 5 nM. GPCS at 2 and 8 mM did not change the number of OC 
with actin rings (10 and 25 min of incubation), while calcitonin caused a complete 
disintegration of the actin ring(s) (Figure 21). 
Figure 21: Effect of GPCS on the disintegration of actin rings. The cells were treated with 2 mM and 8 mM of 
GPCS and 5 nM calcitonin (CT) for 10 and 25 min. The data are presented as the mean ± s.d. (n = 6) of one 
experiment. * p < 0.05, significantly different from control. 
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Effects of GPCS on the resorption activity of osteoclasts  
It was demonstrated by Wetli et al. [Wetli 2005] that GPCS inhibits the resorption activity of 
OCs in vitro. To confirm these results, pit assay experiments were performed. In two 
independent experiments, isolated rat OCs were cultured on dentin slices with 0, 2 and 8 mM 
of GPCS for 24 h. Thereafter, TRAP+ multinucleated (n ≥ 2) cells and resorption pits were 
counted. The number of OCs was similar in all groups (Figure 22). With increasing doses of 
GPCS, the number of pits decreased to 57 %, albeit not significantly (Figure 23). GPCS, at 
8 mM, significantly decreased the number of pits per OC (Figure 24). 0.01 nM of calcitonin 
was used as a positive control. Compared to the control, calcitonin did not change the 
number of OCs, but prevented pit formation, resulting in a pits/OC ratio of zero.  
Figure 22: Effect of GPCS on the number of OCs. Calcitonin was used as a positive control. Two experiments 
were performed, and the data are presented as percent of control (mean ± s.d., n = 16). 
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Figure 23: Effect of GPCS on osteoclastic resorption in the pit assay. Calcitonin was used as a positive control. 
Two experiments were performed, and the data are presented as percent of control (mean ± s.d., n = 16). * p < 
0.05, significantly different from control. 
0
20
40
60
80
100
120
140
Control 2 mM GPCS 4 mM GPCS 8 mM GPCS 0.01 nM Calcitonin
nu
m
be
r 
of
 
pit
s,
 
%
 
of
 
co
n
tro
l, 
m
ea
n
 
±
 
s.
d.
*
 
Figure 24: Effect of GPCS on the ratio of pits per OCs. Two experiments were performed, and the data are 
presented as percent of control (mean ± s.d., n = 16). * p < 0.05, significantly different from control. 
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Effects of GPCS and other structurally related substances on the 
formation of osteoclasts 
Effect of GPCS on the formation of osteoclasts 
To investigate the effect of GPCS on the recruitment of OCs, bone marrow cells were 
incubated with M-CSF and RANKL and varying doses of GPCS for 4 - 5 days. Formed OCs, 
i.e. TRAP+ multinucleated (n ≥ 3) cells were counted. GPCS significantly inhibited 
osteoclastogenesis at concentrations ≥ 1 mM (Figure 25). 
Figure 25: GPCS in bone marrow cell cultures. Two experiments were performed. The data were combined and 
are presented as percent of control (mean ± s.d., n = 12). * p < 0.05, significantly different from control. 
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Effect of substances with structural similarities to GPCS on the formation of 
osteoclasts 
To evaluate structure-function relationship and specificity of the inhibitory effect of GPCS on 
osteoclastogenesis in vitro, γ-glutamyl-cysteine-ethylester, glycyl-cysteine, allyl-cysteine, 
cysteine, glutamyl-glycine and glycyl-valine were tested in cultures of bone marrow cells. 
Substances containing a cysteine moiety inhibited the development of OCs in cultures of 
bone marrow cells with the following potencies: γ-glutamyl-cysteine-ethylester > 
glycyl-cysteine ≈ allyl-cysteine > cysteine (Figures 26-30). 
Figure 26: Structures of γ-glutamyl-cysteine-ethylester, glycyl cysteine, allyl-cysteine and cysteine, ordered by 
their potency in inhibiting osteoclastogenesis.  
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Figure 27: Effect of γ-glutamyl-cysteine-ethylester on the recruitment of OCs. Two independent experiments were 
performed and the results combined. The data are presented as percent of control (mean ± s.d., n = 12). 
* p < 0.05, significantly different from control. 
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Figure 28: Effect of glycyl-cysteine on the recruitment of OCs. Two independent experiments were performed and 
the results combined. The data are presented as percent of control (mean ± s.d., n = 12).  
* p < 0.05, significantly different from control. 
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Figure 29: Effect of allyl-cysteine on the recruitment of OCs. Two independent experiments were performed and 
the results combined. The data are presented as percent of control (mean ± s.d., n = 12).  
* p < 0.05, significantly different from control. 
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Figure 30: Effect of cysteine on the recruitment of OCs. One experiment was performed. The data are presented 
as percent of control (mean ± s.d., n = 6). * p < 0.05, significantly different from control. 
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Glutamyl-glycine and glycyl-valine, substances without a cysteine moiety, did not affect the 
development of OCs in the bone marrow cell culture (Figure 31-33). 
Figure 31: Structures of glutamyl-glycine and glycyl-valine 
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Figure 32: Effect of glutamyl-glycine on the recruitment of OCs. The data are presented as percent of control of 
two independent combined experiments (mean ± s.d., n = 12). 
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Figure 33: Effect glycyl-valine on the recruitment of OCs. The data are presented as percent of control of two 
independent experiments (mean ± s.d., n = 12). 
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8.2.2 Studies to determine the stability of GPCS in simulated gastric 
acid and simulated intestinal fluid 
This section presents the results of the method development and of the stability study of 
GPCS incubated with simulated gastric acid and simulated intestinal fluid. 
Method development 
Determination of GPCS in simulated gastric acid 
To determine GPCS in simulated gastric acid the mobile phase consisted of 25 % of 
solvent A and Spherisorb ODS-1 as stationary phase. A blank run of simulated gastric acid 
was compared with a GPCS spiked sample of simulated gastric acid and showed no 
interference between analyte and matrix. 
Determination of GPCS in simulated intestinal fluid 
In the first experiment to study the stability of GPCS in simulated intestinal fluid, 25 % of 
solvent A was used as mobile phase and Spherisorb ODS-1 as stationary phase. A 
comparison with the blank run of simulated intestinal fluid showed that GPCS interfered with 
the matrix. Thus, an optimisation of the mobile phase was necessary. It was performed by 
utilising 20, 15, 10 and 5 % of solvent A. However, no full baseline separation of the GPCS 
peak and the matrix peaks could be achieved. Hence, another stationary phase, the Shodex 
ODP2 HP-4D material, was tested. Again, different compositions of mobile phases (20, 15, 
10, 7.5 and 5 % of solvent A) were tested. A complete separation of GPCS and matrix peaks 
was obtained at 10 % solvent A. There were no interferences between matrix and analyte. 
To determine the content of GPCS in onion powder, which was incubated with simulated 
intestinal fluid, a mobile phase containing 7.5 % solvent A was most suitable to exclude 
interferences between matrix and analyte. 
An overview of the final experimental conditions is given in Table 15. 
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Table 15: Final conditions for stationary and mobile phases to determine GPCS in various matrices 
Matrix Stationary phase Mobile Phase 
Gastric acid Spherisorb ODS-1 25 % solvent A 
Simulated intestinal fluid Shodex ODP2 HP-4D 10 % solvent A 
Simulated intestinal fluid + onion Shodex ODP2 HP-4D 7.5 % solvent A 
Peak identification 
The retention time for GPCS was 5.8 min (range: 5.6 - 6.0 min) for the Spherisorb column 
and 13.1 min (range: 13.0 – 13.2 min) for the Shodex column. The blank run showed no 
interferences with the analyte.  
Calibration and linearity 
The calibration was linear in the concentration range of 10 to 200 µg/ml (Spherisorb ODS-1 
column) and 5 to 125 µg/ml (Shodex ODP2 HP-4D column), respectively. The linearity data 
are summarised in Table 16. 
Table 16: Calibration data for the quantitation of GPCS with the Spherisorb ODS-1 column obtained by 
performing triplicates for each of the 5 concentration levels (10, 50, 100, 150 and 200 µg/ml), and with the 
Shodex ODP2 HP-4D column obtained by performing triplicates for each of the 3 concentration levels (5, 50 
and 125 µg/ml) 
Column Retention time 
[min] 
m1) b1) Correlation coefficient r 
Spherisorb ODS-1 5.8 3413 – 12.5 0.9998 
Shodex ODP2 HP-4D 13.1 3632 – 12.9 0.9999 
1)y = mx + b; x: amount of GPCS; y: area under the GPCS peak  
Stability of GPCS in simulated gastric acid 
GPCS was exposed in vitro to simulated gastric acid at 37°C. Within 24 h no change in the 
content of GPCS was observed (Figure 34). 
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Figure 34: Stability of GPCS in simulated gastric acid. The results are expressed as percent of the baseline value. 
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Stability of GPCS in simulated intestinal fluid 
The in vitro stability of GPCS in intestinal fluid was evaluated by incubation of GPCS in 
simulated intestinal fluid at 37°C for 24 h. Within  2 h the content of GPCS decreased to less 
than 90 % of baseline. After 6 h, 75 % of GPCS were detectable and after 24 h of incubation 
only 10 % of GPCS were present (Figure 35). 
Figure 35: Stability of GPCS in simulated intestinal fluid (SIF). The results are expressed as percent of the 
baseline value. 
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Stability of GPCS in water 
To check whether ingredients of intestinal enzymes are responsible for the decreasing 
content of GPCS in simulated intestinal fluid, GPCS was incubated in water at 37°C for 24 h. 
GPCS remained stable over the whole incubation time (Figure 36). 
Figure 36: Stability of GPCS in water. The results are expressed as percent of the baseline value. 
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GPCS content of Allium cepa L. incubated in simulated intestinal fluid 
To evaluate the effect of other onion constituents on the stability of GPCS in simulated 
intestinal fluid, lyophilised powder of onion was exposed to simulated intestinal fluid at 37°C 
for 24 h, and the content of GPCS was determined. There was no change of GPCS content 
within 6 h of incubation. After 24 h a decrease of 30 % from the initial GPCS value was 
detectable (Figure 37).  
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Figure 37: GPCS content of onion incubated in simulated intestinal fluid. The results are expressed as percent of 
the baseline value. 
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8.2.3 Pilot studies to determine the pharmacokinetic properties of 
GPCS in rats 
The results of the method development for the determination of GPCS in rat plasma and the 
results of a pharmacokinetic pilot study in rats are presented in this section. 
Method development 
SPE parameters 
SPE was used to prepare the sample prior to analysis. To find suitable conditions for the 
SPE, various SPE columns with different elution procedures were tested. The recovery of 
GPCS in the eluates was determined using HPLC-DAD. The highest recovery of GPCS was 
found when OASIS MAX 3 cc (81 %) columns were used. No GPCS was detected when the 
extraction procedure was performed using Oasis WAX 1 cc columns (Table 17). 
Consequently, Oasis MAX 3 cc was chosen for plasma extraction. 
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Table 17: Recoveries of GPCS after SPE 
SPE column Recovery of GPCS 
[%] 
Oasis MAX 3 cc 81 
Oasis MAX 1 cc 30 
Oasis MCX 1 cc 53 
Oasis WAX 1 cc 0 
Determination of GPCS 
To study the pharmacokinetic properties of GPCS in vivo, 2 rats received 2.5 mg GPCS via 
gavage and 1 rat intravenously. At different time points after administration, blood was 
collected and centrifuged. The plasma was purified using SPE and the level of GPCS 
determined using HPLC-DAD and HPLC-MS/MS. 
Determination of GPCS using HPLC-DAD 
The limit of quantitation of GPCS in plasma using HPLC-DAD was in the µg-range. 
Therefore, no GPCS could be detected in the samples of the pharmacokinetic study. Thus, it 
was tried to improve sensitivity by adding a chromophor to the analyte, i.e. by derivatisation. 
GPCS was derivatised with ortho phthaldialdehyde in the presence of tert-butylmercaptan. 
However, this procedure did not sufficiently improve sensitivity (LOQ: µg-range) and was not 
further used. The next step was the analysis of the samples using HPLC-MS/MS. 
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Determination of GPCS using HPLC-MS/MS 
Optimised parameters for the MRM acquisition mode 
GPCS and I.S. (L-aspartyl-L-phenylalanine) were both eluted after 2.7 min. A mass 
spectrometric separation of the substances was obtained with MS/MS (MRM) in the 
electrospray positive mode. The optimal parameters to analyse GPCS (molecular weight: 
m/z 306) and I.S. (molecular weight: m/z 280) with HPLC-MS/MS in the MRM acquisition 
mode are given in Table 18. 
Table 18: HPLC-MS/MS parameters optimised for the MRM acquisition mode (MRM transitions: 1.: first 
transition, 2.: second transition; Q , quantifier; q, qualifier; MRM ratio: area ratio of peak of the 
1.transition/2.transition; CE, collision energy; CXP, cell exit potential) 
Compound  Molecular 
weight 
Precursor 
[M+H]+ 
DP 
[V] 
MRM transitions CE 
[V] 
CXP 
[V] 
MRM 
ratio 
GPCS  306 307 71 1. 307 → 217.20 (Q) 
2. 307 → 130.10 (q) 
17 
27 
14 
14 
1.78 
I.S. 280 281 66 1. 281.2 → 235.2 
2. 281.2 → 166 
21 
19 
12 
14 
1.32 
 
The GPCS plasma profiles of animal 1 and 2 after administration of GPCS via gavage are 
shown in Figure 38. Maximum GPCS levels (expressed as GPCS-I.S. area ratios) were 
obtained 30 min (animal 1) and 60 min (animal 2) after GPCS administration. Then, the 
GPCS levels dropped to baseline and about 50 % in animal 1 and 2, respectively (within 
180 min post-dosing). Compared to the intravenous application, the oral bioavailability was 
determined to be 1 % for both animals. 
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Figure 38: GPCS rat plasma profiles after administration of GPCS via gavage 
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Animal 3 received GPCS intravenously. The highest level of GPCS was measured 5 min 
after GPCS administration dropping quickly almost to baseline within the observation period 
of 180 min (Figure 39). 
Figure 39: GPCS rat plasma profiles after i.v. administration of GPCS.  
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8.2.4 Pharmacodynamics of substances structurally related to 
GPCS, of GPCS-containing, and of GPCS-free onion 
In this section, the results of three experiments are presented, which were assessed to 
determine the effects of onion containing GPCS, onion without GPCS, allyl-cysteine and 
γ-glutamyl-cysteine-ethylester on bone resorption in rats. 
Feeding protocol 
In the first experiment rats were fed with 23 g of standard diet after their transfer to the 
metabolic cages. They were weighed after 10 days and a loss of weight of about 10 % was 
observed. Thus, the amount of food was not adequate and subsequently was adapted to the 
needs of the rats by first providing them with 25 g food for the first 3 days of the baseline 
phase and afterwards with 30 g. The rats ingested their food within 1 h after it was placed in 
the cages. 20 days after the transfer to the metabolic cages, the rats which were assigned to 
the treatment were weighed again. An increase in weight was observed. In experiments 2 
and 3, rats were fed as stated in section 8.1.4 Experimental design to assess bone 
resorption in vivo. Weighing the rats on days 10 and 20 after their transfer to the metabolic 
cages showed no loss of weight (section 11.4 Appendix 3: Assessment of bone resorption in 
vivo: experiment I to III, weight of rats on day 1, 10 and 20 in metabolic cages). 
Assignment of rats to groups 
After 10 days of [3H] excretion baseline measurement, the rats were assigned to one of 4 
groups with 6 animals each.  
In the first experiment the assignment of rats to the groups was performed by a 
randomisation programme. Calculations which were performed post-experimentally showed 
that the mean cumulative [3H] excretion in each group was not equal in all groups (Figure 
40). 
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Figure 40: Experiment I, mean cumulative urinary [3H] excretion during baseline measurement. Results are 
presented as mean ± s.e.m (n = 6). 
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In the second and third experiment, group assignment was performed as described in  
section 8.1.4 Experimental design to assess bone resorption in vivo. The mean cumulative 
urinary [3H] excretion was equal for all groups at the beginning of the treatment phase 
(Figures 41-42). 
Figure 41: Experiment II, mean cumulative urinary [3H] excretion during baseline measurement. Results are 
presented as mean ± s.e.m (n = 6). 
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Figure 42: Experiment III, mean cumulative urinary [3H] excretion of rats during baseline measurement. Results 
are presented as mean ± s.e.m (n = 6). 
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Effects of GPCS-containing and GPCS-free onion, allyl-cysteine and 
γ-glutamyl-cysteine-ethylester on bone resorption 
In all experiment rats were fed standard diet during the baseline phase (day 1 – 10). During 
the treatment phase (day 11 – 20), they were fed a semi-purified diet containing the test 
compounds or onion powders, respectively.  
In experiment 1, rats received daily semi-purified diet supplemented with 1 g of onion 
containing 20 mg GPCS. Furthermore, the effect of 5 mg and 50 mg allyl-cysteine was 
assessed because allyl-cysteine inhibited OC recruitment in vitro. At the end of the 
experiment, the cumulative urinary [3H] excretion during the treatment phase was 
determined. Rats receiving onion containing GPCS showed a marginal, not significant, 
decrease in cumulative [3H] excretion in comparison to control animals. Allyl-cysteine, at both 
concentrations, did not affect cumulative urinary [3H] excretion (Figure 43).  
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Figure 43: Experiment I: 10 day cumulative urinary [3H] excretion during treatment. Rats were fed a diet 
containing onion with GPCS (GPCSonion 1g), 5 mg allyl-cysteine (Acycs 5 mg), 50 mg allyl-cysteine 
(Acycs 50 mg) or semi-purified diet alone (control) per day over 10 days. The data present treated/control mean 
values ± s.d. (n = 6). 
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At the end of the experiment, rats were euthanised and vertebrae were excised to perform 
microCT analysis. No difference in the BV/TV and connection density between the groups 
was observed (Figures 44-45). 
Figure 44: Experiment I: MicroCT analysis: BV/TV. Rats received a diet containing onion with GPCS 
(GPCSonion 1g), 5 mg allyl-cysteine (Acycs 5 mg), 50 mg allyl-cysteine (Acycs 50 mg) or semi-purified diet alone 
(control) per day over 10 days. The data present treated/control mean values ± s.d. (n = 6). 
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Figure 45: Experiment I: MicroCT analysis: connection density. Rats received a diet containing onion with GPCS 
(GPCSonion 1g), 5 mg allyl-cysteine (Acycs 5 mg), 50 mg allyl-cysteine (Acycs 50 mg) or semi-purified diet alone 
(control) per day over 10 days. The data present treated/control mean values ± s.d. (n = 6). 
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In the second experiment the effect of 1 g onion containing 20 mg GPCS was compared to 
that of 1 g of GPCS-free onion. In addition, γ-glutamyl-cysteine-ethylester was tested at 
100 mg per day, because γ-glutamyl-cysteine-ethylester inhibited OC formation in cultures 
from bone marrow cells. 
Cumulative urinary [3H] excretion from the treatment phase showed no significant change in 
all treatment groups compared to the control. There was no difference in [3H] excretion 
between rats receiving GPCS-containing onion and rats receiving GPCS–free onion (Figure 
46).  
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Figure 46: Experiment II: 10 day cumulative urinary [3H] excretion during treatment. Rats received 1 g onion with 
GPCS (GPCSonion 1g), 1 g onion without GPCS (onion 1 g), 100 mg γ-glutamyl-cysteine-ethylester 
(Glu(CysOEt)) or semi-purified diet alone (control) per day over 10 days. The data present treated/control mean 
values ± s.d. (n = 6). 
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In the third experiment, the dose of onion was increased due to the lack of effects in 
experiments 1 and 2. First, an experiment was performed to determine an increased dose of 
onion to which the rats still respond to with a normal feeding and locomotory behaviour. Six 
7-weeks old rats were transferred to metabolic cages and fed with SODI 2160 for 3 days. 
From the fourth to the seventh day, 2 rats were provided with 30 g SODI 2160 containing 3 g 
of onion, 2 rats received 30 g SODI 2160 containing 5 g of onion and 2 rats were fed SODI 
2160 alone. The rats which were fed with 3 g of onion and those without onions showed 
normal behaviour and feeding patterns. The two rats which were provided with 5 g of onion 
refused to ingest their food within 1 h, showed an altered behaviour and their locomotory 
activity was severely reduced. 
Based on these observations, in the third experiment, rats received semi-purified diet 
supplemented with 3 g onion containing 60 mg GPCS, 3 g onion without GPCS, 1 g onion 
containing 20 mg GPCS or semi-purified diet alone (control) over 10 days.  
After the initial 10 days the cumulative values of urinary [3H] excretion during the treatment 
phase were examined. Compared to the control, the cumulative urinary [3H] excretion was 
decreased to 75 % in the rats fed 3 g GPCS-containing onion and 3 g GPCS-free onion, 
respectively. Rats which were fed GPCS-containing onion at 1 g showed a marginal, but not 
significant decrease in [3H] excretion (Figure 47).  
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Figure 47: Experiment III: 10 day cumulative urinary [3H] excretion during treatment. Rats received 1 g onion with 
GPCS (GPCSonion 1g), 3 g onion with GPCS (GPCSonion 3g), 3 g onion without GPCS (onion 3g) or semi-
purified diet alone (control) per day over 10 days. The data present treated/control mean values ± s.d. (n = 6).  
* p < 0.05, significantly different from control. 
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At the end of the experiment, rats were euthanised and vertebrae were excised to perform 
micro-CT analysis. No difference in the BV/TV and connection density between the groups 
was observed (Figures 48-49). 
Figure 48: Experiment III: MicroCT analysis: BV/TV. Rats received 1 g onion with GPCS (GPCSonion 1g), 3 g 
onion with GPCS (GPCSonion 3g), 3 g onion without GPCS (onion 3g) or semi-purified diet alone (control) per 
day over 10 days. The data present treated/control mean values ± s.d. (n = 6) 
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Figure 49: Experiment III: MicroCT analysis: connection density. Rats received 1 g onion with GPCS (GPCSonion 
1g), 3 g onion with GPCS (GPCSonion 3g), 3 g onion without GPCS (onion 3g) or semi-purified diet alone 
(control) per day over 10 days. The data present treated/control mean values ± s.d. (n = 6) 
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In all three experiments, the course of urinary [3H] excretion was monitored over 20 days of 
baseline and treatment phase. It showed a decrease in urinary [3H] excretion in all groups 
from day 1 to day 20. After dietary change, there was an increase in [3H] excretion from day 
11 to day 12 (Figures 50-52). 
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Figure 50: Experiment I: Daily urinary [3H] excretion of rats during baseline and treatment phase. From day 1 to 
day 10 rats received standard diet. From day 11 rats were administered semi-purified died supplemented with 1 g 
onion containing GPCS (onion 1g), 5 mg allyl-cysteine (Acys 5 mg), 50 mg allyl-cysteine (Acys 50 mg) or SODI 
2160 diet alone (control) over 10 days. The data present mean (n = 6). 
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Figure 51: Experiment II: Daily urinary [3H] excretion of rats during baseline and treatment phase. From day 1 to 
day 10 rats received standard diet. From day 11 rats were provided semi-purified died supplemented with 1 g 
onion containing GPCS (GPCSonion 1g), 1 g onion without GPCS (onion 1g), 100 mg γ-glutamyl-cysteine-
ethylester (Glu(CysOEt)) or semi-purified diet alone (control) per day over 10 days. The data present mean 
(n = 6). 
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Figure 52: Experiment III: Daily urinary [3H] excretion of rats during baseline and treatment phase. From day 1 to 
day 10 rats received standard diet. From day 11 rats were administered semi-purified died containing 1 g GPCS-
containing onion (GPCSonion 1g), 3 g GPCS-containing onion (GPCSonion 3g) and 3 g GPCS-free onion 
(onion 3g) or semi-purified diet alone (control) per day over 10 days. The data present mean (n = 6). 
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8.3 Discussion 
8.3.1 Effect of GPCS on the activity, activation and recruitment of 
osteoclasts in vitro 
Previous studies demonstrated an inhibitory effect of onion on bone resorption [Muhlbauer 
1999, Muhlbauer 2002, Muhlbauer 2003b, Wetli 2005]. GPCS was identified as the active 
compound in vitro showing an inhibition of the resorption activity of OCs [Wetli 2005]. Based 
on these results, further experiments were performed to elucidate the stage of osteoclastic 
resorption affected by the compound: development, activation or activity. 
In our pit assay experiments, a reduced number of pits per OC was observed when cells 
were treated with 8 mM GPCS. Calcitonin, added at 0.01 nM, completely blocked pit 
formation. This concurs with data previously described by Wetli et al. [Wetli 2005]. The effect 
of GPCS on osteoclast activation was examined by determining the percentage of OCs with 
actin ring(s). GPCS did not change the percentage of OCs with actin ring(s). This might have 
either biological or/and technical reasons. On the one hand, GPCS did not exhibit an effect in 
the actin ring assay because it might not influence the activation of the OC, but has effects 
on other stages of the resorption process. On the other hand, the concentration of calcitonin 
which was required to reduce the percentage of OCs with actin ring(s) was 5 nM und thus 
500 fold higher than in the pit assay. The actin ring assay might therefore be less sensitive 
than the pit assay. This may be due to different time of exposure to the substance under 
investigation. OCs in the pit assay were exposed to the test substances for 24 h immediately 
after their attachment to the dentin slices. In contrast, in the actin ring assay, OCs were 
allowed to attach to the glass coverslips for 3 h, when the percentage of OCs with actin rings 
reaches a maximum. Subsequently, the cells were exposed to the substances for 10 and 
25 min.  
GPCS inhibited OC formation at concentrations of 1 mM and higher in our experiments with 
CSF-1/RANKL primed bone marrow cells. This supports our hypothesis that onion may exert 
its inhibition of bone resorption not only by an inhibition of the activity of previously present 
OCs but also by a direct effect on the development of OC lineage cells affecting proliferation, 
differentiation, apoptosis or even cytotoxicity.  
Specificity and structure-function-relationships of the inhibition of OC recruitment by GPCS 
were evaluated by testing peptides, peptide derivatives or dipeptides containing a cysteine 
moiety, a glutamyl moiety, both, or neither one in the molecule. Glutamyl-glycine and glycyl-
valine did not change the number of OCs developing in the culture. All test substances which 
contained a cysteine moiety, γ-glutamyl-cysteine-ethylester, glycyl-cysteine, allyl-cysteine 
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and cysteine, inhibited osteoclastogenesis. These data suggest that the cysteine moiety of 
these molecules might be responsible for the inhibitory effect on the development of OCs. 
Recently, a study has shown that aqueous solutions of onion powder inhibit 
osteoclastogenesis from co-cultures of bone marrow stromal cells and macrophage cells as 
well as RANKL induced ERK, p38 and NF-κB activation in macrophages [Tang 2009]. ERK 
and p38 are mitogen-activated protein kinases which are activated by RANK in OCs and OC 
precursors [Lee 2003]. NF-κB is a transcription factor which is present in the cytoplasm of 
most cell types [Gilmore 2006]. Many studies on bioactivity have been performed with allyl-
cysteine. Allyl-cysteine, a compound derived from garlic (Allium sativum L.), and aged garlic 
extracts were shown to exhibit antioxidant [Amagase 2006], anticarcinogenic [Milner 2006, 
Nagini 2008], hepatoprotective [Gedik 2005] and immunostimulant [Lau 1991] activity. It was 
demonstrated by Geng et al. [Geng 1997] and Ide et al. [Ide 2001] that allyl-cysteine inhibits 
dose-dependently NF-κB activation induced by TNF-α or hydrogen peroxide in human T cells 
and endothelial cells. It was shown that osteoclastogenesis is inhibited in mice deficient of 
NF-κB proteins p 50 and p 52 [Abu-Amer 1997, Iotsova 1997]. NF-κB p 50 and p 52 control 
the differentiation of OC precursor cells induced by RANKL and TNF-α [Yamashita 2007]. 
The question whether the activity of allyl-cysteine, GPCS and the other compounds on OCs 
is related to an effect on NF-κB proteins, ERK or other mechanisms of osteoclastogenesis 
can not yet be answered. 
8.3.2 Studies on the pharmacokinetic properties of GPCS in vitro 
and in vivo 
GPCS was exposed to simulated digestive fluids in vitro. Simulated gastric acid contains 
pepsin, which is extracted from porcine gastric mucosa, and sodium chloride dissolved in a 
solution of hydrochloric acid and water. No change in the concentration of GPCS was 
observed when the compound was incubated under these conditions. Pepsin hydrolyses only 
peptide bonds, but preferentially cleaves hydrophobic, aromatic residues, which might be a 
reason why GPCS was not cleaved. Pepsin also cleaves at the carboxyl side of 
phenylalanine and leucine and to a lesser extent at the carboxyl side of glutamic acid 
residues [Enzyme explorer Pepsin 2008].  
GPCS was also incubated with simulated intestinal fluid, a solution of pancreatin, sodium 
hydroxide and potassium dihydrogen phosphate in water (pH 6.8) [The United States 
Pharmacopoeia 2006]. Within 24 h, a 90 % decrease in the content of GPCS was observed. 
To test if intestinal enzymes are necessarily required for this effect, the content of GPCS was 
monitored in a solution of water over 24 h. GPCS remained stable over this period. 
Therefore, the presence of intestinal enzymes might be essential for degradation. 
Pancreatin, a product of porcine pancreas, contains many enzymes, including amylase, 
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trypsin, lipase, ribonuclease and protease [Data sheet Pancreatin 2008]. GPCS might have 
been cleaved most likely by proteases and probably by trypsin, both hydrolysing peptide 
bonds. Our experiment with onion powder incubated with simulated intestinal fluids over 24 h 
showed no change in GPCS content during the first 6 h. After 24 h, still 70 % of the initial 
GPCS concentration was found. In vitro studies on the influence of onions on digestive 
enzymes of rat pancreas were reported by Ramakrishna et al. [Ramakrishna Rao 2003]. In 
these experiments, pancreatic homogenates were incubated with onion powder and a 
reduced chymotrypsin activity was measured. This might be attributed to protease inhibitors 
present in onion. In a study of Deshimaru et al. [Deshimaru 2003] 3 protease inhibitors were 
purified from onion (OTI 1-3) and were reported to strongly inhibit trypsin, and to a weaker 
extent chymotrypsin activity. The reduced activity of chymotrypsin, trypsin and most likely 
other enzymes, may explain why the GPCS content is less decreased in simulated intestinal 
fluid when GPCS is present in onion matrix than as pure GPCS.  
In a pilot study, we examined the pharmacokinetic properties of GPCS in vivo. The most 
powerful method for the sensitive detection of estimated (sub-)ng levels of GPCS in rat 
plasma was HPLC-MS/MS after sample purification using SPE. SPE was performed with 
Oasis MAX 3 cc columns, resulting in a recovery of about 80 % of GPCS. Oasis MAX is a 
strong mixed-mode anion-exchange polymeric sorbent designed to extract acidic compounds 
in complex matrices such as biological fluids [Brochure: Purity by SPE 2006]. L-Aspartyl-L-
phenylalanine was used as I.S., because of the structural similarity to GPCS, and its stability 
under basic and acidic working conditions. This is very important during the extraction 
process, especially since elution is performed with solutions of ammonium hydroxide and 
formic acid. After SPE, samples were analysed with HPLC-DAD and HPLC-MS/MS. When 
using HPLC-DAD with or without derivatisation, no GPCS was found in the plasma extracts. 
GPCS is devoid of chromophors and thus, its UV absorption lies at a short wavelength at 
195 nm which compromises the sensitivity when using UV detectors. Even derivatisation did 
not improve sensitivity. Consequently, an HPLC-MS/MS method was established which was 
sensitive enough to detect GPCS in the samples. Plasma profiles with typical tmax for 
substances given as single dose were obtained after oral and intravenous application [Bauer 
2002]. The maximum area ratio of GPCS/I.S. was reached within 1 h for orally administered 
GPCS and the absolute bioavailability determined was about 1 %. This raises the question 
whether suitable concentrations of GPCS could be reached at the site of action indicating 
that either metabolites of GPCS might be responsible for an effect or GPCS is highly potent. 
The latter possibility is rather unlikely, because GPCS inhibited the activity and development 
of OCs in vitro at concentrations of 8 mM and from 1 mM and higher, respectively. The low 
bioavailability of the oral pure GPCS application might be due to pancreatic enzymes in the 
intestinal fluid, as shown by our in vitro experiments. But also other factors, such as 
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transporters, and physical conditions, for example tight intracellular conjunctions and the lipid 
characteristics of the cell membrane, might limit bioavailability [Pauletti 1997]. Due to the fact 
that the GPCS content is less decreased in simulated intestinal fluid when GPCS is present 
in onion, it is very likely that plasma levels of GPCS after oral onion administration would be 
higher than after administration of pure GPCS.  
8.3.3 Studies on the pharmacodynamics of GPCS in vivo 
When looking at the presence of GPCS in various plants (see chapter 6 Part I: Determination 
of GPCS in various plants), we found onions devoid of GPCS and onion containing high 
amounts of GPCS (20 mg per g dry onion powder). Each material was tested in 
pharmacodynamic studies to investigate, whether onion without GPCS exhibits other effects 
on bone resorption in rats than onion containing GPCS. In addition, allyl-cysteine and 
γ-glutamyl-cysteine-ethylester were tested as well, because these compounds showed a 
decrease of OC recruitment in vitro. To estimate the amount of bone resorption, we 
determined the urinary [3H] excretion of rats chronically labelled with [7-3H(N)]-tetracycline, a 
model, which was previously used and validated in several other studies [Antic 1996, Egger 
1994, Muhlbauer 1990, Muhlbauer 1995, Muhlbauer 1999, Muhlbauer 2002, Muhlbauer 
2003b, Wetli 2005]. [7-3H(N)]-Tetracycline is incorporated into the bone and excreted into 
urine during bone resorption. In the first experiment, the feeding protocol was adopted from 
Wetli et al. [Wetli 2005]. Within the first 10 days of our experiment, the rats lost approximately 
10 % of weight. Thus, lateron, the amount of food was increased and a gain in weight was 
observed. In experiment II and III, the daily food dose, which was found in experiment I to fit 
best to the need of the rats, was given from the start of the experiment, preventing loss of 
weight. After 10 days of [3H] excretion baseline measurement, rats were assigned to different 
groups. In experiment I, rats were assigned randomly. Post-experimental analysis revealed, 
however, that the groups secreted unequal mean cumulative amounts of 
[7-3H(N)]-tetracycline at the start of the treatment phase. Thus, not all groups had the same 
initial conditions, eventually giving rise to false results. Consequently, the mode of 
assignment was changed for the following experiments. A computer programme was 
designed which calculated an optimal assignment of the rats to the groups leading to an 
equal mean cumulative urinary [3H] excretion at the beginning of the treatment phase.  
In experiment I and II, a 1-g daily dose of onion containing GPCS was tested and exhibited 
no significant differences in the cumulative urinary [3H] excretions, BV/TV, and connection 
density compared to control. In contrast to our results, in studies performed by Mühlbauer et 
al. and Wetli et al. [Muhlbauer 1999, Muhlbauer 2002, Muhlbauer 2003b, Wetli 2005], 1 g of 
onion significantly inhibited cumulative urinary [3H] excretions. However, the content of 
GPCS present in the onions used by these authors is not known and might have been higher 
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than in our experiments. This might explain the lack of effect in our studies. As expected from 
the results of the [3H]tetracycline assay and probably due to the short time of exposure to the 
substance, no differences between the groups in BV/TV and connection density of the 
cancellous bone were detected. The dose of onion was increased in experiment III. Daily 
doses of 3 g of onion, either containing or being devoid of GPCS, significantly inhibited 
cumulative urinary [3H] excretion compared to control whereas 1 g of onion containing GPCS 
showed only marginal effects. There was no difference between the mean cumulative [3H] 
excretion in both 3 g onion groups. This data suggests that, besides GPCS, other 
substances contribute to the inhibitory effects of onion on bone resorption in vivo. GPCS was 
previously found to be an active component following a bioassay based protocol [Wetli 2005], 
which, however, does not exclude the presence of other bone active components. It may 
also be possible that the contribution of GPCS to the inhibition of bone resorption by GPCS 
is insignificant, the observed in vitro effects at high concentrations being unspecific and other 
components of the onions mediating the biological response. While these possibilities 
warrant further investigations in the role of onions on bone resorption, it should be kept in 
mind that only one experiment supplementing the animals’ daily diet with 3 g of onion was 
performed and the data needs to be reproduced. The previous validation and use of the 
[3H]tetracycline model in several studies [Antic 1996, Egger 1994, Muhlbauer 1990, 
Muhlbauer 1995, Muhlbauer 1999], however, provide some strength to these results.  
BV/TV and connection density were equal between all groups in experiment III which may be 
explained by the short exposure time (10 days) of the test substances. Long-term studies 
over 6 weeks on adult female rats have shown that onion-containing diet significantly 
decreases ovariectomy-induced bone loss and increases BV/TV and trabecular number and 
separation [Huang 2008].  
In our experiments, allyl-cysteine and γ-glutamyl-cysteine-ethylester did not inhibit bone 
resorption in vivo, although they inhibited OC development in vitro. This may be due to an 
insufficient dose and/or to a low bioavailability of the two compounds in vivo, so that no 
adequate concentrations result at the site of action.  
Monitoring the urinary [3H] excretions over 20 days, we observed a decrease in the excretion 
from day 1 to day 20 which is attributed to the biological half-life of [7H-3(N)]-tetracycline. An 
increase of urinary [3H] excretions from day 11 to 12 was most probably induced by the 
change of diet on day 10 from standard to semi-purified diet without any plant derived 
inhibitors of bone resorption. This increase in the urinary [3H] excretions was lower in groups 
with a significantly decreased mean cumulative [3H] excretion. Since the food supplements 
and the semi-purified diet are given from the same time (day 10), the effect observed in this 
assay is an inhibition of the stimulation of bone resorption, rather than on the decrease of a 
normal physiological resorption. The data demonstrate that the food supplements can be 
Part III: Pharmacodynamic and pharmacokinetic properties of GPCS in vitro and in vivo 95 
 
used to inhibit bone resorption. Therefore, this strategy might be a means for the prevention 
of bone loss. 
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The results of the present investigations show that GPCS does not only affect OC activity in 
vitro, but also OC recruitment, probably due to the cysteine moiety of the compound. As 
mentioned previously, studies by Tang et al. [Tang 2009] demonstrated that an inhibition of 
RANKL-induced osteoclastogenesis by onion might proceed via ERK, p38 and NF-κB 
pathways. Allyl-cysteine, a compound which was tested in our in vitro OC recruitment assay 
as well, inhibited osteoclastogenesis, and has previously been reported to inhibit NF-κB 
activation [Geng 1997, Ide 2001]. The question whether the in vitro activity of allyl-cysteine, 
GPCS, cysteine, γ-glutamyl-cysteine-ethylester and glycyl-cysteine on OCs is related to an 
effect on NF-κB, ERK or p38 could be answered by testing the compounds in the assays 
described by the authors previously mentioned. The results of our kinetic studies on GPCS 
and onion suggest that the oral application of GPCS in a solution of sodium chloride is 
unsuitable because of the low bioavailability, which might be attributed to pancreatic 
enzymes cleaving GPCS, especially proteases and trypsin. However, the presence of 
protease inhibitors in onions probably prevents the cleavage of GPCS and might therefore 
increase the bioavailability of the compound. Onion containing GPCS and onion without 
GPCS exhibited the same amount of inhibition of bone resorption in vivo. Due to the fact, that 
onion without GPCS exhibits an effect, we can postulate that either GPCS has no effect or is 
not the only substance from onion exerting an effect on bone resorption. Therefore, in further 
research, first priority should be given to the synthesis of GPCS to provide sufficient material 
for further in vivo studies. Future experiments using natural GPCS-free onions spiked with 
synthetic GPCS should clarify, to which extent GPCS contributes to the inhibition of bone 
resorption. If GPCS is involved in an inhibition of bone resorption, the exact mechanism 
should be elucidated and toxic effects should be excluded.  
A variety of plants were tested according to the presence of GPCS. None of these plants 
contained GPCS and thus, the question which compounds are responsible for their in vivo 
bone resorption inhibiting effect remains unanswered. The active compounds might be 
isolated using a bioassay in vitro and the structure might be investigated using MS and NMR. 
Afterwards, the activity should be confirmed in vivo.  
References 99 
 
 
 
 
 
10 References 
References 100 
 
Abu-Amer Y and Tondravi MM. NF-kappaB and bone: the breaking point. Nat Med 3(11), 
1189-90 (1997). 
Ali M, Thomson M and Afzal M. Garlic and onions: their effect on eicosanoid metabolism and 
its clinical relevance. Prostaglandins Leukot Essent Fatty Acids 62(2), 55-73 (2000). 
Amagase H. Clarifying the real bioactive constituents of garlic. J Nutr 136(3 Suppl), 716S-
725S (2006). 
Antic VN, Fleisch H and Muhlbauer RC. Effect of bisphosphonates on the increase in bone 
resorption induced by a low calcium diet. Calcif Tissue Int 58(6), 443-8 (1996). 
Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM and 
Suda T. Commitment and differentiation of osteoclast precursor cells by the sequential 
expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J 
Exp Med 190(12), 1741-54 (1999). 
Aubin JE, Lian JB, Stein GS and Goldring SR. in Primer on the Metabolic Bone Diseases 
and Disorders of Mineral Metabolism, 20-9 (2006). 
Bantscheff M, Schirle M, Sweetman G, Rick J and Kuster B. Quantitative mass spectrometry 
in proteomics: a critical review. Anal Bioanal Chem 389(4), 1017-31 (2007). 
Baron R. in Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism (ed. 
Favus M) Lippincott Williams & Wilkins, London (1999). 
Bauer, Frömming and Führer. Lehrbuch der pharmazeutischen Technologie, 7. Auflage 
Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart (2002). 
Block E. The chemistry of garlic and onions. Sci Am 252(3), 114-9 (1985). 
Block E. The Organosulur Chemistry of the Genus Allium - Implications for the Organic 
Chemistry of Sulfur. Angew Chem Int Ed Engl 31,1135-78 (1992). 
Bonjour JP, Burckhardt P, Dambacher M, Kraenzlin ME and Wimpfheimer C. Epidemiology 
of osteoporosis. Schweiz Med Wochenschr 127(16), 659-67 (1997). 
Boyle WJ, Simonet WS and Lacey DL. Osteoclast differentiation and activation. Nature 
423(6937), 337-42 (2003). 
Breu W. Allium cepa L. (Onion) Part 1: Chemistry and analysis. Phytomedicine 3(3), 293-306 
(1996). 
Brochure: Purity by SPE. Oasis sample Extraction Products. Waters Corporation (2006). 
Brochure: Solid Phase Extraction. Gilson, www.gilson.com (2006). 
Brown NM and Setchell KD. Animal models impacted by phytoestrogens in commercial 
chow: implications for pathways influenced by hormones. Lab Invest 81(5), 735-47 (2001). 
Carson JF and Boggs LE. The Synthesis and Base-Catalyzed Cyclization of (+)- and (-)-cis-
S-(1-propenyl)-L-cysteine Sulfoxides. J Org Chem 31(9), 2862-4 (1966). 
Consensus development conference. Diagnosis, prophylaxis, and treatment of osteoporosis. 
Am J Med 94(6), 646-50 (1993). 
Coolong TM and Randle WM. Temperature Influences Flavor Intensity and Quality in 'Granex 
33' Onion. J Amer Soc Hort Sci 128(2), 176-81 (2003). 
Corea G, Fattorusso E, Lanzotti V, Capasso R and Izzo AA. Antispasmodic saponins from 
bulbs of red onion, Allium cepa L. var. Tropea. J Agric Food Chem 53(4), 935-40 (2005). 
References 101 
 
Cubbage JW, Guo Y, McCulla RD and Jenks WS. Thermolysis of Alkyl Sulfoxides and 
Derivatives: A Comparison of Experiment and Theory. J Org Chem 66(26), 8722-8736 
(2001). 
Data sheet Pancreatin. Sigma-Aldrich Co., www.sigma-aldrich.com (2008). 
Dawson-Hughes B, Kleerekoper M and Lane N. in Primer on the Metabolic Bone Diseases 
and Disorders of Mineral Metabolism, 257-9 (2006). 
Dempster DW, Lian JB and Goldring SR. in Primer on the Metabolic Bone Diseases and 
Disorders of Mineral Metabolism 7-11, (2006). 
Deshimaru M, Watanabe A, Suematsu K, Hatano M and Terada S. Purification, amino acid 
sequence, and cDNA cloning of trypsin inhibitors from onion (Allium cepa L.) bulbs. Biosci 
Biotechnol Biochem 67(8), 1653-9 (2003). 
Egger CD, Muhlbauer RC, Felix R, Delmas PD, Marks SC and Fleisch H. Evaluation of 
urinary pyridinium crosslink excretion as a marker of bone resorption in the rat. J Bone Miner 
Res 9(8), 1211-9 (1994). 
El-Demerdash FM, Yousef MI and El-Naga NI. Biochemical study on the hypoglycemic 
effects of onion and garlic in alloxan-induced diabetic rats. Food Chem Toxicol 43(1), 57-63 
(2005). 
Enzyme explorer Pepsin. Sigma-Aldrich Co., www.sigma-aldrich.com (2008). 
Europäische Pharmakopöe. 5. Ausgabe, Grundwerk 2005. Deutscher Apotheker Verlag 
Stuttgart (2005). 
Fontanals N, Marce RM and Borrull F. New materials in sorptive extraction techniques for 
polar compounds. J Chromatogr A 1152(1-2), 14-31 (2007). 
Freeman GG and Mossadeghi N. Studies on the relationship between water regime and 
flavour strength in watercress (Rorippa nasturtium-aquaticum (L) Hayek), cabbage (Brassica 
oleracea capitata) and onion (Allium cepa). J Hort Sci 48, 365-78 (1973). 
Freeman GG and Whenham RJ. Thiopropanal S-oxide, alk(en)yl thiosulphinates and 
thiosulphonates: Simulation of flavour components of Allium species. Phytochemistry 15(1), 
187-90 (1976). 
Gedik N, Kabasakal L, Sehirli O, Ercan F, Sirvanci S, Keyer-Uysal M and Sener G. Long-
term administration of aqueous garlic extract (AGE) alleviates liver fibrosis and oxidative 
damage induced by biliary obstruction in rats. Life Sci 76(22), 2593-606 (2005). 
Geng Z, Rong Y and Lau BH. S-allyl cysteine inhibits activation of nuclear factor kappa B in 
human T cells. Free Radic Biol Med 23(2), 345-50 (1997). 
Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25(51), 
6680-4 (2006). 
Griffiths G, Trueman L, Crowther T, Thomas B and Smith B. Onions--a global benefit to 
health. Phytother Res 16(7), 603-15 (2002). 
Harada S and Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 
423(6937), 349-55 (2003). 
Harvey N, Earl S, Cooper C, Kleerekoper M and Lane N. in Primer on the Metabolic Bone 
Diseases and Disorders of Mineral Metabolism, 244-8 (2006). 
Heaney RP, Kleerekoper M and Lane N. in Primer on the Metabolic Bone Diseases and 
Disorders of Mineral Metabolism, 255-7 (2006). 
References 102 
 
Hennion MC. Solid-phase extraction: method development, sorbents, and coupling with liquid 
chromatography. J Chromatogr A 856(1-2), 3-54 (1999). 
Huang TH, Muhlbauer RC, Tang CH, Chen HI, Chang GL, Huang YW, Lai YT, Lin HS, Yang 
WT and Yang RS. Onion decreases the ovariectomy-induced osteopenia in young adult rats. 
Bone 42(6), 1154-63 (2008). 
Ide N and Lau BH. Garlic compounds minimize intracellular oxidative stress and inhibit 
nuclear factor-kappa b activation. J Nutr 131(3s), 1020S-6S (2001). 
Iotsova V, Caamano J, Loy J, Yang Y, Lewin A and Bravo R. Osteopetrosis in mice lacking 
NF-kappaB1 and NF-kappaB2. Nat Med 3(11), 1285-9 (1997). 
Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 
103(2A), 20S-25S; discussion 25S-6S (1997). 
Jones MG, Hughes J, Tregova A, Milne J, Tomsett AB and Collin HA. Biosynthesis of the 
flavour precursors of onion and garlic. J Exp Bot 55(404), 1903-18 (2004). 
Kasai T and Larsen PO. Chemistry and Biochemistry of γ-Glutamyl Derivates from Plants 
Including Mushrooms (Basidomycetes). Prog Chem Nat Prod 39, 173-285 (1980). 
Kopsell DA and Randle WM. Selenium Affects the S-alk(en)yl Cysteine Sulfoxides among 
Short-day Onion Cultivars. J Amer Soc Hort Sci 124(3), 307-11 (1999). 
Kuttan R, Nair NG, Radhakrishnan AN, Spande TF, Yeh HJ and Witkop B. The isolation and 
characterization of gamma-L-glutamyl-S-(trans-1-propenyl)-L-cysteine sulfoxide from sandal 
(Santalum album L). An interesting occurrence of sulfoxide diastereoisomers in nature. 
Biochemistry 13(21), 4394-400 (1974). 
Lancaster JE and Shaw ML. [gamma]-Glutamyl peptides in the biosynthesis of S-alk(en)yl--
cysteine sulphoxides (flavour precursors) in Allium. Phytochemistry 28(2), 455-60 (1989). 
Lancaster JE and Shaw ML. Metabolism of [gamma]-glutamyl peptides during development, 
storage and sprouting of onion bulbs. Phytochemistry 30(9), 2857-9 (1991). 
Lanzotti V. The analysis of onion and garlic. J Chromatogr A 1112(1-2), 3-22 (2006). 
Lau BH, Yamasaki T and Gridley DS. Garlic compounds modulate macrophage and T-
lymphocyte functions. Mol Biother 3(2), 103-7 (1991). 
Lawson LD, Wang Z-YJ and Hughes BG. y-Glutamyl-S- alkylcysteines in garlic and other 
Allium ssp.: Precursors of age-dependent trans-1-propenyl thiosulfinates. J Nat Prod 54(2), 
436-44 (1991). 
Lee ZH and Kim HH. Signal transduction by receptor activator of nuclear factor kappa B in 
osteoclasts. Biochem Biophys Res Commun 305(2), 211-4 (2003). 
Luque-Garcia JL and Neubert TA. Sample preparation for serum/plasma profiling and 
biomarker identification by mass spectrometry. J Chromatogr A 1153(1-2), 259-76 (2007). 
Mabboux D. Computer Programme: "MaRDat", details on request. Personal Communication 
Bern (2007). 
Matikkala EJ and Virtanen AI. On The Quantitative Determination of the Amino Acids and γ-
Glutamylpeptides of Onion. Acta Chem Scand 21 10, 2891-3 (1967). 
McGartland CP, Robson PJ, Murray LJ, Cran GW, Savage MJ, Watkins DC, Rooney MM 
and Boreham CA. Fruit and vegetable consumption and bone mineral density: the Northern 
Ireland Young Hearts Project. Am J Clin Nutr  80(4), 1019-23 (2004). 
Milner JA. Preclinical perspectives on garlic and cancer. J Nutr 136(3 Suppl), 827S-31S 
(2006). 
References 103 
 
Muhlbauer RC. Rutin cannot explain the effect of vegetables on bone metabolism. J Bone 
Miner Res 16(5), 970-1 (2001). 
Muhlbauer RC and Fleisch H. A method for continual monitoring of bone resorption in rats: 
evidence for a diurnal rhythm. Am J Physiol 259(4 Pt 2), R679-89 (1990). 
Muhlbauer RC and Fleisch H. The diurnal rhythm of bone resorption in the rat. Effect of 
feeding habits and pharmacological inhibitors. J Clin Invest 95(4), 1933-40 (1995). 
Muhlbauer RC and Li F. Effect of vegetables on bone metabolism. Nature 401(6751), 343-4 
(1999). 
Muhlbauer RC, Li F, Lozano A, Reinli A and Tschudi I. Some vegetables (commonly 
consumed by humans) efficiently modulate bone metabolism. J Musculoskelet Neuronal 
Interact 1(2), 137-40 (2000). 
Muhlbauer RC, Lozano A, Palacio S, Reinli A and Felix R. Common herbs, essential oils, 
and monoterpenes potently modulate bone metabolism. Bone 32(4), 372-80 (2003a). 
Muhlbauer RC, Lozano A and Reinli A. Onion and a mixture of vegetables, salads, and herbs 
affect bone resorption in the rat by a mechanism independent of their base excess. J Bone 
Miner Res 17(7), 1230-6 (2002). 
Muhlbauer RC, Lozano A, Reinli A and Wetli H. Various selected vegetables, fruits, 
mushrooms and red wine residue inhibit bone resorption in rats. J Nutr 133(11), 3592-7 
(2003b). 
Mütsch-Eckner M and Sticher O. Reversed phase high-performance liquid chromatography 
of S-alk(en)yl-L-cysteine derivatives in Allium sativum including the determination of (+)-S-
allyl-L-cysteine sulphoxide, gamma-L-glutamyl-S-allyl-cysteine and gamma-L-glutamyl-S-
(trans-1-propenyl)-L-cysteine. J Chromatogr. 625, 183-90 (1992). 
Nagini S. Cancer chemoprevention by garlic and its organosulfur compounds-panacea or 
promise? Anticancer Agents Med Chem 8(3), 313-21 (2008). 
Nakamura I, Duong le T, Rodan SB and Rodan GA. Involvement of alpha(v)beta3 integrins in 
osteoclast function. J Bone Miner Metab 25(6), 337-44 (2007). 
Namyslo J and Stanitzek C. A Palladium-Catalyzed Synthesis of Isoalliin, the Main Cysteine 
Sulfoxide in Onions (Allium cepa). Synthesis(20), 3367-9 (2006). 
New SA, Robins SP, Campbell MK, Martin JC, Garton MJ, Bolton-Smith C, Grubb DA, Lee 
SJ and Reid DM. Dietary influences on bone mass and bone metabolism: further evidence of 
a positive link between fruit and vegetable consumption and bone health? Am J Clin Nutr 
71(1), 142-51 (2000). 
Pauletti GM, Gangwar S, Siahaan TJ, Aube J and Borchardt RT. Improvement of oral 
peptide bioavailability: Peptidomimetics and prodrug strategies. Adv Drug Deliv Rev 27(2-3), 
235-56 (1997). 
Pixley FJ and Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in 
action. Trends Cell Biol 14(11), 628-38 (2004). 
Poole CF, Gunatilleka AD and Sethuraman R. Contributions of theory to method 
development in solid-phase extraction. J Chromatogr A 885(1-2), 17-39 (2000). 
Pragst F, Herzler M and Erxleben BT. Systematic toxicological analysis by high-performance 
liquid chromatography with diode array detection (HPLC-DAD). Clin Chem Lab Med 42(11), 
1325-40 (2004). 
Prentice A. Diet, nutrition and the prevention of osteoporosis. Public Health Nutr 7(1A), 227-
43 (2004). 
References 104 
 
Pretsch E, Clerc T and Seibl J. Tabellen zur Strukturaufklärung organischer  Verbindungen 
mit spektroskopischen Methoden, Springer, Berlin (2001). 
Price P. Standard Definitions of Terms Relating to Mass Spectrometry : A report from the 
Committee on Measurements and Standards of the American Society for Mass 
Spectrometry. J Am Soc Mass Spectrom 2(4), 336-48 (1991). 
Prynne CJ, Mishra GD, O'Connell MA, Muniz G, Laskey MA, Yan L, Prentice A and Ginty F. 
Fruit and vegetable intakes and bone mineral status: a cross sectional study in 5 age and 
sex cohorts. Am J Clin Nutr 83(6), 1420-8 (2006). 
Putnam SE, Scutt AM, Bicknell K, Priestley CM and Williamson EM. Natural products as 
alternative treatments for metabolic bone disorders and for maintenance of bone health. 
Phytother Res 21(2), 99-112 (2007). 
Ramakrishna Rao R, Platel K and Srinivasan K. In vitro influence of spices and spice-active 
principles on digestive enzymes of rat pancreas and small intestine. Nahrung 47(6), 408-12 
(2003). 
Randle WM. Onion germplasm interacts with sulfur fertility for plant sulfur utilization and bulb 
pungency. Euphytica 59(2), 151-6 (1992). 
Randle WM. Increasing Nitrogen Concentration in Hydroponic Solutions Affects Onion Flavor 
and Bulb Quality. J Amer Soc Hort Sci 125(2), 254-9 (2000). 
Randle WM, Block E, Littlejohn MH, Putman D and Bussard ML. Onion (Allium cepa L.) 
Thiosulfinates Respond to Increasing Sulfur Fertility. J Agric Food Chem 42(10), 2085-8 
(1994). 
Rose P, Whiteman M, Moore PK and Zhu YZ. Bioactive S-alk(en)yl cysteine sulfoxide 
metabolites in the genus Allium: the chemistry of potential therapeutic agents. Nat Prod Rep 
22(3), 351-68 (2005). 
Ross FP, Lian JB and Goldring SR. in Primer on the Metabolic Bone Diseases and Disorders 
of Mineral Metabolism 30-5, (2006). 
Roux C, Bischoff-Ferrari HA, Papapoulos SE, de Papp AE, West JA and Bouillon R. New 
insights into the role of vitamin D and calcium in osteoporosis management: an expert 
roundtable discussion. Curr Med Res Opin 24(5), 1363-70 (2008). 
Rücker G, Neugebauer M and Willems GG. Instrumentelle pharmazeutische Analytik 
Wissenschaftliche Verlagsgesellschaft, Stuttgart (2001). 
Schwenkglenks M and Szucs T. in Osteoporose und Stürze im Alter (ed. BAG) BAG, Bern, 
(2004). 
Shaw ML, Lancaster JE and Lane GA. Quantitative analysis of the major gamma-glutamyl 
peptides in onion bulbs (Allium Cepa L.). J Sci Food Agric 48, 459-67 (1989). 
Smith RM. Before the injection--modern methods of sample preparation for separation 
techniques. J Chromatogr A 1000(1-2), 3-27 (2003). 
Squires G. Francis Aston and the mass spectrograph. J Chem Soc 23, 3893-900 (1998). 
Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT and Martin TJ. Modulation of 
osteoclast differentiation and function by the new members of the tumor necrosis factor 
receptor and ligand families. Endocr Rev 20(3), 345-57 (1999). 
Suzuki H, Nakamura I, Takahashi N, Ikuhara T, Matsuzaki K, Isogai Y, Hori M and Suda T. 
Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated 
with protein kinase A in osteoclasts. Endocrinology 137(11), 4685-90 (1996). 
References 105 
 
Tang CH, Huang TH, Chang CS, Fu WM and Yang RS. Water solution of onion crude 
powder inhibits RANKL-induced osteoclastogenesis through ERK, p38 and NF-kappaB 
pathways. Osteoporos Int 20(1), 93-103 (2009). 
Teitelbaum SL, Abu-Amer Y and Ross FP. Molecular mechanisms of bone resorption. J Cell 
Biochem 59(1), 1-10 (1995). 
Teitelbaum SL and Ross FP. Genetic regulation of osteoclast development and function. Nat 
Rev Genet 4(8), 638-49 (2003). 
Teyssier C, Amiot MJ, Mondy N, Auger J, Kahane R and Siess MH. Effect of onion 
consumption by rats on hepatic drug-metabolizing enzymes. Food Chem Toxicol 39(10), 
981-7 (2001). 
The United States Pharmacopoeia. USP 29. Rockville, 3171 (2006). 
Tucker KL, Chen H, Hannan MT, Cupples LA, Wilson PW, Felson D and Kiel DP. Bone 
mineral density and dietary patterns in older adults: the Framingham Osteoporosis Study. 
Am J Clin Nutr 76(1), 245-52 (2002). 
Tucker KL, Hannan MT, Chen H, Cupples LA, Wilson PW and Kiel DP. Potassium, 
magnesium, and fruit and vegetable intakes are associated with greater bone mineral density 
in elderly men and women. Am J Clin Nutr 69(4), 727-36 (1999). 
Vaananen HK, Zhao H, Mulari M and Halleen JM. The cell biology of osteoclast function. J 
Cell Sci 113 ( Pt 3)377-81 (2000). 
Van den Broek LAGM, Breuer ML, Liskamp RMJ and Ottenheijm HCJ. Total synthesis and 
absolute configuration of the natural dipeptide gamma-glutamylmarasmine. J Org Chem 
52(8), 1511-7 (1987). 
Virtanen AI and Matikkala EJ. Proofs of the Presence of γ-glutamyl-S-(1-propenyl)-
sulphoxide and cycloalliin as original compounds in onion (Allium cepa). Suomen Kemistilehti 
34(10), 114 (1961a). 
Virtanen AI and Matikkala EJ. The Structure of the γ-glutamyl peptide 4 isolated from onion 
(Allium cepa) γ-L-glutamyl-S-(1-propenyl)-cysteinesulphoxide. Suomen Kemistilehti 34(7), 84 
(1961b). 
Wetli HA, Brenneisen R, Tschudi I, Langos M, Bigler P, Sprang T, Schurch S and Muhlbauer 
RC. A gamma-glutamyl peptide isolated from onion (Allium cepa L.) by bioassay-guided 
fractionation inhibits resorption activity of osteoclasts. J Agric Food Chem 53(9), 3408-14 
(2005). 
World Health Organisation. Assessment of Fracture Risk and its Application to Screening for 
Postmenopausal Osteoporosis. WHO Technical Report Series 843 (1994). 
Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda 
M, Matsuo K, Xing L and Boyce BF. NF-kappaB p50 and p52 regulate receptor activator of 
NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor 
differentiation by activating c-Fos and NFATc1. J Biol Chem 282(25), 18245-53 (2007). 
Yang J, Meyers KJ, van der Heide J and Liu RH. Varietal differences in phenolic content and 
antioxidant and antiproliferative activities of onions. J Agric Food Chem 52(22), 6787-93 
(2004). 
Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, 
Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N 
and Suda T. Osteoclast differentiation factor is a ligand for 
osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. 
Proc Natl Acad Sci USA 95(7), 3597-602 (1998). 
References 106 
 
Yu TH, Wu CM, Rosen RT, Hartman TG and Ho CT. Volatile compounds generated from 
thermal degradation of alliin and deoxyalliin in an aqueous solution. J Agric Food Chem 
42(1), 146-53 (1994). 
 
Appendices  107 
 
 
 
 
 
 
11 Appendices 
Appendices  108 
 
 
11.1 Appendix 1: List of Abbreviations 
ANOVA Analysis of variance 
AUC Area under the curve 
b Broad (NMR) 
BSA Bovine serum albumin 
BV/TV Bone volume/total volume quotient 
CE Collision energy 
CXP Cell exit potential 
d Douplet (NMR) 
DAD Diode array detection 
DP Declustering potential 
ESI Electrospray ionisation 
FBS Fetal bovine serum 
FBS Hia Heat-inactivated fetal bovine serum 
GC-MS Gas chromatography - mass spectrometry 
GPCS γ-Glutamyl-propenyl-cysteine sulfoxide  
HEPES N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) solution 
HPLC High performance liquid chromatography 
i.d. Inner diameter 
I.S. Internal standard 
IS Ion spray voltage 
LOQ Limit of quantitation 
m Multiplet (NMR) 
M-CSF Macrophage colony-stimulating factor 
MEM Minimum essential medium with Earle’s salts and without phenol red 
α-MEM alpha-Minimum essential medium with Earle’s salts 
MEM Hank’s Minimum essential medium with Hanks’s salts 
MP Melting point 
MPLC Medium pressure liquid chromatography 
MRM Multiple reaction monitoring mode 
MS Mass spectrometry 
m/z Mass to charge 
NMR Nuclear magnetic resonance spectroscopy 
OC Osteoclast 
PBS Phosphate buffered saline 
PFA Paraformaldehyde 
P/S Penicillin-streptomycin-solution 
q Quartet (NMR) 
QQQ Triple quadrupole mass spectrometer 
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RANKL Receptor activator of NF-κB ligand 
RP Reverse-phase 
r.s.d. Relative standard deviation 
s Singlet (NMR) 
s.d. Standard deviation 
SIF Simulated intestinal fluid 
SPE Solid phase extraction 
TRAP Tartrate resistant acid phosphatase 
UV Ultraviolet 
VIS Visible 
v/v Volume to volume ratio 
w/w Weight to weight ratio 
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11.2 Appendix 2: List of suppliers 
Agilent Technologies, Wilmington, USA 
Applied Biosystems, MDS Sciex, Concord, ON, Canada 
Bachem, Burgdorf, Switzerland 
BALZERS UNION Limited, Balzers, Liechtenstein 
Charles River Wiga GmbH, Sulzfeld, Germany 
Chiron Corporation, Emeryville, CA, USA 
GERSTEL AG, Sursee, Switzerland 
Gibco, Lubio Sciences GmbH, Lucerne, Switzerland 
Gilson, Villiers La Bel, France 
Infochroma, Zug, Switzerland 
Kliba-Mühlen, Kaiseraugst, Switzerland 
Machery-Nagel, Oensingen, Switzerland 
Marienfeld GmbH & Co. KG Lauda-Königshofen, Germany 
Merck, Dr. Grogg Chemie AG, Stettlen, Switzerland 
Molecular Probes, Invitrogen, Lubio Sciences GmbH, Lucerne, Switzerland 
Packard, Top Lab GmbH, Rickenbach, Switzerland 
Peprotech London, UK 
Perkin Elmer, Schwerzenbach, Switzerland 
Phenomenex, Torrance, CA, USA 
Scanco Medical AG, Basserdorf, Switzerland 
Schleicher & Schuell, Sigma-Aldrich, Buchs, Switzerland 
Sigma-Aldrich, Buchs, Switzerland 
Thermo Shandon, Pittsburgh, USA 
Waters, Baden-Dättwil, Switzerland 
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11.3 Appendix 3: Composition of SODI 2134 and SODI 2160 
diet powders 
11.3.1 Composition of SODI 2160 diet powder 
Ingredient Concentration  
in % 
 Ingredient Concentration  
in mg/kg 
Corn starch 56  Iron 80 
Casein 20  Zinc 38 
Dextrose 10  Copper 5 
Cellulose 4  Iodine 0.8 
Pork fat 3  Manganese 11 
Arginine 0.71  Selenium 0.2 
Lysine 1.38  Vitamin A 1.34 
Methionine 0.56  Vitamin D3 0.025 
Methionine, cystine 0.62  Vitamin E 100 
Tryptophan 0.25  Vitamin K3 4 
Threonine 0.72  Vitamin B1 6 
Calcium 1.1  Vitamin B2 6 
Phosphorus 1.2  Vitamin B6 7 
Magnesium 0.15  Vitamin B12 0.05 
Sodium 0.30  Nicotinic acid 30 
Potassium 0.70  Pantothenic acid 16 
Chlorine 0.25  Folic acid 2 
   Biotin 0.2 
   Choline 1000 
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11.3.2 Composition of SODI 2134 diet powder 
Ingredient Concentration  
in % 
 Ingredient Concentration  
in mg/kg diet 
Corn starch 59  Iron 78 
Soybean meal 20  Zinc 33 
Potato protein 9  Copper 8 
Refined soybean oil 3.5  Iodine 1.3 
Oats 2.4  Manganese 15 
Dextrose 2  Selenium 0.2 
Casein 2  Vitamin A 3.35 
Arginine 1.06  Vitamin D3 0.025 
Lysine 1.20  Vitamin E 100 
Methionine 0.40  Vitamin K3 4 
Methionine, cystine 0.60  Vitamin B1 6 
Tryptophan 0.24  Vitamin B2 6 
Threonine 0.78  Vitamin B6 7 
Calcium 0.17/1.1*  Vitamin B12 0.05 
Phosphorus 0.20/1.2*  Nicotinic acid 30 
Magnesium 0.19  Pantothenic acid 16 
Sodium 0.19  Folic acid 2 
Potassium 0.71  Biotin 0.2 
Chlorine 0.32  Choline 1000 
* after preparation 
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11.4 Appendix 3: Assessment of bone resorption in vivo: 
experiment I to III, weight of rats on day 1, 10 and 20 in 
metabolic cages 
  Experiment I Experiment II Experiment III 
Rat No. Day 1 Day 10 Day 20 Day 1 Day 10 Day 20 Day 1 Day 10 Day 20 
1 284 250 - 237 245 - 256 260 - 
2 294 269 - 254 262 - 273 271 290 
3 280 253 292 235 230 - 327 310 - 
4 290 256 294 226 232 - 267 267 295 
5 269 243 - 230 233 - 307 294 320 
6 299 266 303 243 243 266 292 278 300 
7 260 235 282 242 240 - 292 278 - 
8 323 284 - 250 252 - 306 300 320 
9 290 263 300 260 265 - 275 274 295 
10 263 239 282 227 237 - 320 296 320 
11 305 275 - 235 240 270 292 277 300 
12 260 240 - 236 247 - 302 300 310 
13 250 231 272 266 275 312 275 276 297 
14 265 240 - 250 254 285 259 260 286 
15 276 250 298 255 254 273 247 250 280 
16 260 240 280 260 260 286 272 270 - 
17 295 252 296 246 247 - 270 270 290 
18 307 268 - 264 267 295 250 254 280 
19 280 256 - 242 247 268 225 235 - 
20 291 257 295 260 260 287 247 254 285 
21 280 264 294 230 235 - 250 256 - 
22 305 250 289 258 266 288 269 270 - 
23 308 278 309 268 272 290 267 270 - 
24 300 259 295 270 270 - 248 250 275 
25 262 237 270 285 285 305 296 288 310 
26 288 248 282 278 275 290 299 283 - 
27 275 250 285 245 260 - 266 268 - 
28 298 263 301 265 263 290 264 269 292 
29 270 240 281 310 292 310 260 250 - 
30 290 263 290 275 268 - 296 291 317 
31 290 256 300 237 245 - 267 263 280 
32 273 243 285 277 275 300 270 271 - 
33 274 248 288 270 275 - 270 269 290 
34 256 223 - 265 265 300 300 297 307 
35 - - - 290 292 320 292 284 310 
36 - - - - - - 250 254 280 
Mean 283 253 290 255 258 291 276 272 297 
s.d. 18 14 10 20 17 15 23 17 14 
 
 
